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 Viruses are obligatory intracellular pathogens requiring host machinery for 
survival and reproduction. Differing from living organisms, which can grow where 
nutrients are available, viruses absolutely require hijacking of host machineries to 
complete their life cycle. Enveloped viruses evolved to have dedicated strategies to 
passively sense environmental cues to ensure that initiation of infection occurs at the 
correct moment and place. One general strategy used by enveloped viruses is to 
precisely control activation of their envelope glycoprotein just prior entry into host 
cells.   
 Influenza A virus (AIV) is the causative agent of influenza illness and causes 
both economical and public health problems globally and annually. As a successful 
pathogen infecting a wide range of animals, IAV excels in sensing the environment to 
ensure efficient infection by employing two sequential activating steps during viral 
entry: proteolytic cleavage for priming of the hemagglutinin (HA) and low-pH-triggered 
conformational changes allowing release of the fusion peptide.  
 Proteolytic cleavage of influenza HA controls viral pathogenesis by influencing 
viral growth rate and viral tropism. The primary sequence and tertiary structure of the 
HA determine the overall properties of HA activation and hence, viral pathogenesis.  
 Mutations on the primary sequence of the HA cleavage site affect viral 
activation in two dimensions, 1) HA activation efficiency and 2) alteration in protease 
repertoire for HA activation. The former modulates viral growth kinetics and the later 
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is important for viral tropism. Mutations that modifies HA tertiary structure also play an 
important role in viral activation, in particular virus growth.   
 In this thesis, I describe three interrelated studies of mutations on primary and 
tertiary structure of HA and their consequence on HA cleavage and viral 
pathogenesis. These mutations also allow influenza virus to interact with prokaryotic 
pathogens and open up another dimension in virus-bacteria-host interactions and 
synergy.  
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  CHAPTER 1 
INTRODUCTION 
1.1  The Influenza Problem 
1.1.1 Influenza Infection 
Influenza, commonly known as “flu”, is an upper respiratory disease that is 
caused by influenza viruses. Flu symptoms were first described by the ancient Greek 
physician, Hippocrates of Cos dating back to 412 BC (1). Presently, influenza viruses 
are still circulating around the world, infecting and causing disease in vertebrates. 
Among the three different genera of influenza viruses, influenza A virus (IAV) and 
Influenza B virus were first isolated in 1933 in the human population (2). IAV 
originated from waterfowls where it adapted well and causes only asymptomatic 
infection in its natural hosts (3). IAV becomes pathogenic and causes a range of 
symptoms after zoonotic transmission to different hosts. IAV becomes widely spread 
and infects a wide range of vertebrates, from whale to bat (4, 5). Due to the huge 
diversity of IAV, they are categorized into subtypes which are determined by the two 
surface viral glycoproteins, hemagglutinin (HA) and neuraminidase (NA) (6, 7). Each 
subtype has a unique antigenic profile but share rather similar biological properties. 
Currently, 18 HA and 11 NA subtypes have been identified (8). Although most of 
them reside in waterfowls (9), two IAV subtypes, H1N1 and H3N2 are continuously 
infecting the human population and causing seasonal influenza each year. 
1.1.2 Seasonal and Pandemic Influenza 
Seasonal human IAV infects 3 to 5 million people annually (9). Clinical 
presentations of influenza infection include fever, cough, sore throat, running nose, 
muscle pain, headaches, fatigue and sometime diarrhea (10). In normal 
circumstances, patients infected by IAV typically require 5 to 7 days to recover; 
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hence, such infections lead to loss in productivity. According to the Centers for 
Disease Control and Prevention (11), the estimated economical loss in the United 
States due to influenza related illness is in the range of 27 to 87 billion US Dollars 
(USD) per year (12, 13). Influenza infections can also lead to death; annual mortality 
associated with IAV is around 250,000 to 500,000 deaths (9). People with sub-
optimal/immature immune system, such as infants, senior citizens and pregnant 
women or having chronic underlying diseases, such as obesity, diabetes and 
bacterial infections are particularly of high risk (14, 15). Differing from seasonal 
influenza, pandemic influenza emerges unpredictably and shows less discrimination 
between healthy and sub-optimally healthy individuals in terms of disease severity 
and prevalence (16). In the last century, three pandemic influenza viruses have 
emerged by gene exchange between two or more influenza viruses through a 
process called antigenic shift (6). Due to lack of immunity in the human population, 
pandemic viruses are able to spread across the population in a short period of time. 
For instance, in 1918, the “Spanish flu” infected up to 40% of the global population 
and killed more than 50 million people (16, 17).  The most recent influenza pandemic 
in 2009 arose from a triple reassortment event between human, avian and swine 
influenza viruses (18). Within two months after the first reported case in Mexico, the 
viruses spread throughout the entire northern hemisphere and the World Health 
Organization (WHO) announced to the world a phase 6 global pandemic alert (19). 
Fortunately, catastrophic consequences of that pandemic were avoided thanks to the 
relatively low virulence of the virus and advancements in the current medical system. 
However, the 2009 pandemic still cost an estimated 71 to 167 billion USD in 
economical loss on top of the regular seasonal influenza (20).  
1.1.3 Avian Influenza 
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Avian influenza virus (AIV) was directly involved in three of the pandemic 
influenza outbreaks and the 1918 pandemic which also has a speculated avian origin 
(6, 18). Moreover, the increase in incidences of humans infected by AIV is becoming 
a new public health concern (21, 22). Modern human practices in poultry and 
livestock industries provided effective ways for influenza viruses to transmit between 
species. Indeed, people infected by avian influenza viruses are mainly farm workers 
who are exposed to or in close contact with avian species (21, 23). In 1997, a highly 
pathogenic avian influenza virus (HPAI) H5N1 emerged in Hong Kong, spread locally 
and killed 6 people out of 18 infected patients (23, 24). Although the Hong Kong 
government had been effective in controlling HPAI locally by exterminating all live 
poultries in the city, it is still a reoccurring public health issue in Southeast Asia (25). 
Subsequently, HPAI has already infected more than 600 people worldwide with an 
extremely high fatality rate (~60%) according to the CDC. Despite limited incidences 
showing HPAI transmission from human to human in nature, recent reports have 
shown that HPAI could transmit between humans efficiently. Two separate research 
groups were able to show that after serial passages (>10) of HPAI in ferrets, the virus 
was able to transmit between animals via aerosol. Mapping of the viral mutations 
revealed that HPAI only requires 2 mutations from PB1 and NP, 4 mutation on HA 
and 1 mutation on PB2 to acquire such phenotype (26, 27). Ferrets serve as the best 
model animal for influenza infection due to the similarity of its upper respiratory 
system and clinical presentation with the human ones (28). These reports not only 
demonstrate the possibility of a “humanized” HPAI but also raise the concern of a 
potential escape of the “humanized” HPAI from laboratories. Open access of the 
protocol for humanizing HPAI also raised alarm for the potential misuse of such 
viruses by bioterrorist (29).  
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1.1.4 Influenza Vaccine and Therapeutic Drugs 
Protective vaccines are formulated every year to protect the human population 
from seasonal influenza prior to the influenza season, which spans from November to 
April in the northern hemisphere. However, due to the unpredictability of pandemic 
influenza, it is impossible to have a vaccine ready for an unknown pathogen. A 
universal vaccine eliciting neutralizing antibodies to a broad range of influenza 
viruses by targeting a conserved region, such as the matrix protein 2 (M2) or the stalk 
domain of HA, would constitute the holy grail of influenza vaccine development (30-
32). However, a recent report has shown antibody dependent enhancement (5) after 
administration of a broadly neutralizing vaccine in a swine model, questioning the 
safety and feasibility of such a vaccine (33, 34). Furthermore, influenza viruses 
mutate rapidly to change epitopes over time, limiting such vaccine strategy for long 
term usage. Therapeutic drugs are available for treating influenza infections. Two 
groups of drugs exist: the NA inhibitors, zanamivir (Relenza) (35) and oseltamivir 
(Tamiflu) (36); and the ion channel blockers, amantadine (Symmetrel) and 
rimantadine (Flumadine) are currently used to combat influenza infection (37). The 
M2 ion channel inhibitors are effective only when administrated in the early stage of 
infection, which limits its actual use as a prophylactic drug (38). Furthermore, as 
predicted, many influenza viruses are gaining resistance to the drugs due to 
influenza’s high mutation rate, for instance, R292K, N294S or H273Y mutation in NA 
gave rise to virus resistance to oseltamivir (39, 40). Therefore, a better understanding 
of influenza life cycle is important for developing new strategies or combination 
therapy to combat the virus.  
1.2 The Influenza Particle 
1.2.1 Influenza Virion  
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Influenza A viruses are enveloped negative-strand segmented RNA viruses 
belonging to Orthomyxoviridae family. The size of IAV genome is 13.5 kb length that 
is separated into eight viral RNA (vRNA) segments. By alternative splicing, the 
genome encodes for up to 11 to 14 viral proteins (41). Influenza virions are 
pleiomorphic but mainly can be classified into two morphological groups, either 
spherical or filamentous. Spherical virions are usually found in laboratory adapted 
(possibly by embryonic chicken egg (ECE) and tissue cultures) viruses which are 
around 100 nm in diameter. Filamentous virions are found in clinical samples from 
natural infections and have similar width as spherical virions but can be up to 20 m 
in length (42, 43). Multiple determinants, such as the Ala41 in matrix protein 1 (M1) 
and the M2 amphipathic helix located in the first 17 amino acid of the cytoplasmic tail 
have been reported to be associated with filamentous morphology in vitro (44, 45). A 
recent study has shown that serial passages of spherical virus, PR8 in guinea pig 
change the virus’ morphology from spherical to filamentous. In contrast, passaging 
filamentous virus, A/Udorn/72/H3N2 (Udorn) in tissue culture converts the virus into 
spherical morphology (46). Although clinical samples are always associated with 
filamentous morphology, which argues its importance in in vivo infections, the 
functional aspects of filamentous influenza are uncertain (47, 48). A recent study 
shows that filamentous virus grows slower and has decreased cell-to-cell spread 
compared to spherical virus in vitro (49). The underlying mechanism of how 
filamentous viruses are produced is still largely unknown.  
Inside each influenza virus is a genome set in the form of ribonucleoproteins 
(RNPs), a combination of vRNA segments and proteins. Each vRNA segment is 
coated with nucleoproteins (NP) with each individual NP binding around ~24 RNA 
nucleotides  (50). At the 3’ end of each segment is the heterotrimeric RNA dependent 
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RNA polymerase (RdRP) composed of polymerase acidic (PA), polymerase basic 1 
(PB1) and polymerase basic 2 (PB2), all together, they form the viral RNP (vRNP). 
Viral RNPs are surrounded by the M1 and wrapped by host derived lipid envelope 
that is obtained from plasma membrane lipid rafts which are enriched in cholesterol 
and sphingolipids (SPs) (51). On the virion, M2 has a ratio of 1:10  to 1:100 compared 
to HA and forms proton channels between within lipid envelopes that are essential for 
releasing the vRNPs into the cytoplasm after membrane fusion (52). Two surface 
glycoproteins are found on the surface of the virus membrane, HA and NA for viral 
entry and egress. There are about 500 molecules of HA homotrimer on the surface 
and they are found as clustered islands on each virus (53). HA is responsible for 
receptor binding and membrane fusion of the virus during the entry step. NA is a 
tetrameric sialidase which hydrolyzes terminal sialic acids and releases the virion 
during viral egress. There are about 120 NA molecules on each influenza virion which 
are mainly located at the budding end of the virus (53). Some trace amounts of host 
derived proteins are found on the surface of flu particles, that are incorporated either 
by active or passive mechanisms, including cytoskeletal proteins, annexins, glycolytic 
enzymes and tetraspanins (54). Some of these have been shown to be involved in 
the viral life cycle or pathogenesis. For instance, annexin A2 was shown to recruit 
plasminogen (Plg) for HA activation during influenza entry, and actin was shown to be 
essential for influenza entry in polarized cells (55, 56).  
1.3 Influenza Proteins 
1.3.1 The Influenza RNA-dependent RNA polymerase (RdRP) 
Influenza requires its own RdRP for transcription of (+) mRNA and replication 
of (-) vRNA inside host cells. The influenza RdRp is a 250 kDa heterotrimer 
composed of three subunits: PB1, PB2 and PA. The C-terminus and N-terminus of 
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PB1 binds to PB2 and PA respectively (57, 58). PB1 is the core of the RdRP as it is 
responsible for elongation during RNA replication and transcription and its active site 
resembles the typical RdRP motif with Ser-Asp-Asp at position 444 to 446 (59). PB2 
is required for the initial step of “cap snatching” (a process in which the 5’ m7GTP cap 
is stolen from cellular mRNAs and used as a primer for viral RNA transcription) and 
initiates RNA replication as it binds to cellular mRNA 5’ m7GTP cap. The binding of 
PB2 and mRNAs involves two aromatic amino acids, 357 His and 404 Phe that 
sandwiches the m7GTP cap by stacking interactions (60). PA is a member of the Pro-
Asp-Asp/Glu-X-Lys family of endonucleases with two Mn2+ ions at its active site (61). 
Its primary function is to cleave off the m7GTP cap from the 5’ end of cellular mRNAs. 
PA also has proteolytic function involving two residues: S624 and T157, however, the 
function of such activity is unknown but essential, as mutation of those residues 
affects RNA replication (62). As human cells do not have RdRP, it is an attractive 
drug target for treatment of influenza infection. Indeed, the influenza RdRP inhibitor 
T-705 is currently being developed and is under a phase II clinical trial.   
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Figure 1.1. Influenza Virion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Horimoto T. and Kawaoka Y, Nature Review Microbiology 3, 591 
(2005) (63) 
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1.3.2 Hemagglutinin (HA) 
HA is a monomeric rod-shaped molecule with the C-terminus residing in the 
cytoplasm (Type I transmembrane protein) and assembles into a trimer which 
projects out as a “spike” from the viral membrane (41). HA trimers are also prototypes 
of class I fusion protein, which form extensive -helices. Also, as a class I fusion 
protein, they need to be proteolytically cleaved to expose the protein’s fusion peptide 
(64). A typical HA trimer is about 180 to 240 kDa, 135 Å tall and is held together in a 
coiled-coil structure by hydrophobic interactions. HA monomers are produced as a 
single molecule, HA0, which contains two functional domains, HA1 and HA2. Before 
HA activation, HA1 and HA2 are covalently linked together; after activation, the two 
domains are held together by di-sulfide bonds (65). HA1 is the “crown” of HA which is 
responsible for receptor binding; depending on the host range of the virus, it can bind 
to two differentially linked sialic acids, SA2,6Gal and/or SA2,3Gal (65). 
Experiments using fluorescent lectins, Sambucus nigra agglutinin (SNA) which binds 
SA2,6Gal and Maackia amurensis agglutinin (MAA) which binds SA2,3Gal, reveal 
that the human upper respiratory tract contains mainly SA2,6Gal whereas deeper in 
the respiratory tract, in bronchioles and alveoli, both SA2,6Gal and SA2,3Gal are 
found (66, 67). On the other hand, avian respiratory and intestinal tracts mainly 
contain SA2,3Gal (67). Generally, influenza viruses with HAs that are able to bind to 
SA2,6Gal mainly infect humans while viruses with HAs that can bind SA2,3Gal are 
more likely to infect avian species. Other host species, such as swine, have both 
SA2,6Gal and SA2,3Gal on their respiratory tract, and are hence susceptible to 
infecting with virus containing any HAs and could potentially serve as a mixing vessel 
for avian and human influenza allowing for recombination events to occur and 
generation of novel virus strains (68, 69). Therefore, the sialic acid binding specificity 
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of influenza virus is an important determinant for the viral host range. Several 
mutations have been identified that control the sialic acid binding properties of 
influenza HA and hence modulate viral tropism. One particular example is the single 
mutation, HA-190E which is able to switch the HA from binding SA2,3Gal to 
SA2,6Gal (70). The recent advances in glycan array technology allow researchers 
to test HA binding on more complex glycan structures, and test parameters such as 
chain length, branching patterns, sulfation and fucosylation.  
HA2 is the “stem” region of HA and is essential for membrane fusion. Before 
HA activation, HA2 is covalently linked to the C-terminus of HA1 and locked in a 
closed position. Unlike HA1, HA2 is highly conserved between subtypes especially in 
the fusion peptide region which is located at the first 22 N-terminal amino acid of HA2 
(41). Mutational analyses have shown that the HA fusion peptide has very low 
tolerance for mutations (71). At neutral pH, activated HA2 is folded under HA1 and the 
fusion peptide is buried inside a pocket in the center of the coiled-coil stem, 
mimicking the closed position of a “Swiss-army knife” (65). The neutral pH 
conformation of HA2 is trapped in a metastable state (72). In acidic conditions, HA2 
undergoes loop to helix conformation change that creates a coiled-coil structure that 
projects the fusion peptide out for 100 Å and allowing insertion into the endosomal 
membrane (65). After the viral and cellular membranes are bought into close 
proximity, HA2 folds back and forms a trimeric hairpin structure that pulls the two 
membranes towards each other. The inner leaflet of the endosomal membrane and 
the outer leaflet of the viral envelope fuse together by hydrophobic interactions and 
reach a metastable hemifusion state. The actual trigger for pore formation is still 
unknown. Recent biophysical studies using total internal reflection fluorescence 
(TIRF) microscopy to monitor single particle fusion events support the notion that HA 
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fusion is a multistep process which likely require three distinct steps (73). Although 
the exact number of HA molecules required for fusion varies between reports, which 
is likely due to differences in assumptions and models used, the consensus is that 
very low amounts of HA molecules (less than 10) are required for successful fusion to 
occur.  
Influenza HA is also the main target for the host immune system and it faces 
constant pressure from neutralizing antibodies. In particular, five regions on HA1, Sa, 
Sb, Ca1, Ca2 and Cb are the most immunogenic among the entire virion (74). HAs 
are separated into two phylogenetic groups, group 1 (H1, 2, 5, 6, 8, 9, 11, 12, 13 and 
16) and group 2 (H3, 4, 7, 10, 14, and 15). Cross-reactive antibodies are more likely 
to react within the members of the same group as they are more antigenically similar. 
For instance, the V(H)1-69 antibody has been identified as a broadly neutralizating 
antibody that neutralizes all group 1 HAs whereas Fab CR8020 was shown to 
neutralize all group 2 HAs (30, 75). To counteract the pressures from the immune 
system, HA1 undergoes constant mutation (antigenic drift); one way the virus evades 
neutralizing antibodies is the introduction of glycosylation sites on the HA protein. Asn 
(N)-linked glycosylation have a conserve motif of Asn-X-Ser/Thr where X can be any 
amino acid except Pro (76). Glycans are bulky sugar molecules that mask the 
antigenic site from neutralizing antibodies (65). However, adding glycosylation sites 
could potentially mask the receptor binding domain (RBD) of HA as well (77). 
Therefore, the number of glycosylation sites on a particular HA is finely tuned to allow 
for immune evasion and receptor binding affinity (78). It is interesting to note that a 
tissue culture adapted virus, A/Puerto Rico/8/1934 H1N1 (PR8), has lost most of its 
glycosylation sites on HA1. A likely explanation for this is that there is no immune 
pressure in vitro (79). 
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Figure 1.2. Influenza HA 
 
 
            
 
 
Adapted from Amorij JP et al., Pharm Res 25, 1256 (2008) (80)  
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1.3.3 Nucleoprotein (NP) 
Similarly to all other negative sense RNA viruses, influenza virus encodes the 
NP to coat its RNA genome to form the ribonucleoprotein (RNP) complex. NP is a 
498 amino acid long protein with an overall positive charge and is post-translationally 
modified with phosphorylation at Ser3 (41). NP is a multi-functional protein involved in 
many different steps of the viral life cycle including RNA replication, RNP trafficking 
and packaging (81). NP performs these functions by interacting with viral and cellular 
proteins. For instance, the nucleus localization signal (NLS) of NP interacts with 
cellular importin  to allow nuclear import of viral RNPs (82). NP is a co-factor for 
RNA elongation through an interaction with the RdRP complex. Studies have shown 
that viral RNA without NP can initiate transcription but fail to continuously elongate 
(83). NP also controls the viral life cycle by regulating the switch between RNA 
transcription and RNA replication (84). Although host factors may also be involved, 
NP is an important factor in this switching process. Later in the viral life cycle, NP 
interacts with M1 which initiates packaging of RNP into influenza virion (85, 86). NP is 
also a drug target for treating influenza infection. A recent study showed that 
administration of drugs that promote oligomerization of NP rescues mice from lethal 
infection of influenza virus (87).  
1.3.4 Neuramindase (NA) and Matrix Protein 2 (M2) 
Influenza NA is produced as a 55 - 60 kDa monomer with six -sheets 
arranged in a propeller formation and assembles as a tetramer on the virion surface 
(88). As it names implies, NA is a sialidase which catalyzes hydrolysis of sialic acid. 
Its primary function is to release influenza virus from sialic acid receptors and mucus 
during viral egress (89). Influenza C virus does not have NA but instead has a 
haemagglutinin-esterase (HEF) protein that carries the function of HA and NA on one 
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protein (90). Similarly to HA, NA is also antigenic and thus, constantly mutating to 
escape from host immune system selective pressure. Currently, there are 11 NA 
subtypes known that are separated into two groups based on sequence homology 
(41). In addition to its role in viral egress, NA is also involved in viral entry. Studies 
have shown that NA is responsible for removal of non specific viral receptors in 
mucins and cilia which allows penetration of influenza virus in target cells (91). NA 
has also been shown to act as a viral receptor binding protein and be involved in 
binding to the cell surface directly. WSN NA has also been shown to bind 
plasminogen (Plg) and facilitate HA cleavage during influenza activation (92-94).  
M2 is a splice variant encoded on segment 7. M2 is produced as an 11 kDa -
helix monomer with its cytoplasmic tail undergoing palmitoylation and phosphorylation 
post-translational modification (95, 96). M2 assembles into tetramers on the viral 
membrane and forms proton channels that are critical for viral uncoating during entry 
(97). The crystal structure of M2 reveals the H+ conductance mechanism controlled 
by the His37 and Trp41 amino acid clusters (98). A small portion of the M2 protein is 
exposed on the viral surface and its sequence is highly conserved and therefore, 
would constitute a good candidate epitope for generating universally neutralizating 
antibodies (32). Both NA and M2 are attractive targets for drug development and NA 
and M2 inhibitors are currently used as therapeutics for treating influenza infection 
(covered in “1.1.4 Influenza Vaccine and Therapeutic Drugs”). 
1.3.5 Matrix Protein 1 (M1) and Nuclear Export Protein (99) 
Segment 7 encodes both M1 and M2 proteins by alternative splicing (41). M1 
is the most abundant protein in the influenza virion and mainly plays a role in viral 
assembly. During viral assembly, M1 is translocated into the nucleus and interacts 
with vRNP and the nucleosome (85). Such interactions are thought to initiate 
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dissociation of vRNPs from the nuclear matrix and allow export of vRNPs out of the 
nucleus. M1 also interacts with NEP which mediates nuclear export for the whole 
vRNP-M1-NEP complex by interacting with the host export machinery Crm1 and 
nucleoporins (100, 101). NEP is a splice variant of segment 8 and is not incorporated 
into influenza virions.  The N-terminus of NEP contains a Met/Leu rich nuclear export 
signal and is critical for vRNP export (102). NEP regulates RNP export by binding to 
the NLS of M1 to prevent it from being imported back to the nucleus (103). M1 protein 
also plays a role in viral morphogenesis that has been covered in section 1.2 
“Influenza Particles”.                
1.3.6 Non Structural Protein 1 (NS1) 
NS1 is a dimeric nuclear protein which is highly expressed in influenza 
infected cells but not incorporated inside virions. NS1 is an antagonist of type I 
interferon (IFN) which is part of the innate immune response for viral infections in 
eukaryotes (104). NS1 is composed of 2 functional domains: the N-terminal dsRNA 
binding domain and an effecter domain (104-106). Expression of the dsRNA binding 
domain is sufficient to block IFN production suggesting its important role for 
antagonizing IFN in infected cells. NS1 antagonize IFN at transcriptional level by 
targeting multiple host factors upstream of the IFN signaling cascade. NS1 inhibits 
transcription factors including Interferon regulatory factor-3 (IRF-3) and nuclear factor 
B (NF-B). NS1 also binds to RIG-I and prevents the downstream signaling for IFN 
activation (107-109). Furthermore, NS1 also interacts with TRIM25 which is the 
upstream regulator of RIG-I further preventing IFN induction (110). The Protein 
Kinase R (PKR) and RNase L pathways are also inhibited by NS1 protein by 
sequestering viral dsRNA which is the activator for both pathways (111, 112). The 
effector domain is also important for the viral life cycle as deletion of the effecter 
 16 
 
domain attenuates virus infection mice (113). The effector domain blocks host mRNA 
translation by interacting with the cleavage and polyadenylation specificity factor 
(CPSF) which halts mRNA nuclear export for translation (114).    
1.3.7 Accessory Proteins 
 Ten core proteins that we were covered previously are expressed among all 
IAV. Four non-essential proteins, PB1-F2, PB1-N40, PA-X and M42 are expressed in 
a strain dependent manner and modulate viral pathogenesis without affecting the 
normal life cycle of influenza virus (115, 116). PB1-F2 is initiated from AUG4 in the +1 
open reading frame (ORF) of segment 2 (117). The length of PB1-F2 ranges from 79 
to 90 amino acids long depending on the strain (116, 118). PB1-F2 localizes to the 
mitochondria and is pro-apopototic and pro-inflammatory (117, 119, 120). PB1-F2 
has also been shown to be associated with increased virulence in bacterial co-
infection setting, suggesting synergistic effects between viruses expressing the 
protein and bacteria (121). PB1-N40 was first discovered in 2009 and is a truncated 
version of PB1 that lacks the first 39 amino acid of the N-terminus which is the region 
critical for interaction with PA (122, 123). Although viruses lacking PB1-N40 have 
slower growth rates, the function of the protein is still unclear. PA-X is a 252 amino 
acids long protein encoded in segment 3 via ribosomal frameshifting. Eliminating PA-
X production from the 1918 “Spanish flu” virus increases viral pathogenesis and 
induces a global change in host transcription profile. The function of PA-X is still 
unclear but is important in modulating host response and viral pathogenesis (124). 
M42 is the latest non-essential protein discovered in 2012 from a splice variant in 
segment 7. Its primary function is to compensate the loss of M2 ion channel in tissue 
culture adapted viruses. The actual function of M42 in natural infection is still unclear 
(125).      
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Figure 1.3 Organization and alternative splicing of Influenza genes 
 
 
 
 
 
 
 
 
 
 
Adapted from ViralZone 2012, SIB Swiss Institute of Bioinformatics  
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1.4 Influenza Entry 
1.4.1 Influenza Attachment and Endocytosis 
Human IAV mainly infects non-ciliated epithelial cells from the upper 
respiratory tract and in a minority of cases, penetrates deep into lungs and infects 
type I and type II pneumocytes (126). Autopsy analysis of patients that died of H5N1 
HPAI infection have shown diffuse alveolar damage indicating infection in the lower 
respiratory tract whereas type II pneumocytes are the main cell types being infected 
(99, 127). In avian species, influenza viruses target the epithelial cells of both the 
respiratory and gastro-intestinal tracts (21). Regardless of the host and tissue, 
influenza viruses first need to penetrate through physical barriers including the mucus 
and ciliated cells to reach the surface of target cells. Once have the virus reached the 
apical side of cell surfaces, human influenza HA binds to N-acetylneuraminic acid 
linked to the penultimate galactose by a 2,6 linkage (SA2,6Gal), whereas avian 
influenza HA binds to the same sugar molecule but with a 2,3 linkage (SA3,3Gal) 
(41). The actually trigger for influenza endocytosis is still unknown; however, there is 
evidence that the multivalent binding between HA and receptor triggers the activation 
of receptor tyrosine kinase and induces a signal for endocytosis (128, 129). Early 
electron microscopy and recent stochastic optical reconstruction microscopy 
(STORM) data reveal that up to 65% of influenza particles are wrapped around by a 
clathrin coated pit on the surface or are found completely inside clathrin coated 
lattices (CCL) indicating the involvement of clathrin mediated endocytosis (CME) 
(129). Biochemical analysis using dominant negative mutants of ezrin1, a membrane-
microfilament linker, demonstrated its critical role in influenza CME (130). The other 
35% of influenza viruses are found inside non-clathrin coated pit suggesting 
alternative pathways for influenza entry. STORM and use of chemical inhibitors also 
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demonstrated that influenza particles use lipid-raft-dependent caveolin mediated 
endocytosis (129, 131). Interestingly, influenza entry is not affected after blockage of 
both CME and caveolin mediated endocytosis by various drugs and dominant 
negative constructs, suggesting a non-clathrin, non-caveolin endocytosis route of 
entry (132). Recently, a dynamin-independent pathway which resembles some 
aspects of macropinocytosis has been identified and has been shown as the major 
entry pathway for filamentous influenza virus (133, 134). 
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Figure 1.4. Influenza endocytosis  
 
 
 
                            
 
 
 
 
 
Adapted from Karlsson Hedestam GB et al., Nature Review Microbiology 6, 143 
(2008) (135) 
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1.4.2 Membrane Fusion 
After endocytosis, influenza viruses are wrapped inside endosomal vesicles. 
The endosomal machinery is a system dedicated to intracellular trafficking of 
macromolecules inside eukaryotic cells (136). Endosomes constantly fuse with other 
intracellular vesicles during the process of maturation which adds different surface 
markers as identifiers of their nature and also dictate the destination of the cargos 
(137). For instance, early endosomes (EE) with Rab5 on their surface mature into late 
endosome (LE) which are decorated with Rab7 and eventually fuse with the 
lysosome for cargo degradation. EE can also recycle back to the plasma membrane 
via the recycling endosome (RE). Large macromolecules, such as influenza virus, are 
targeted to the lysosome for degradation; therefore, in order to initiate productive 
infection, influenza viruses need to escape from the endosome. HA mediated 
membrane fusion and uncoating both require an acidic environment (low pH) as a 
trigger to release viral contents into the cytoplasm (138). The pH value inside the EE 
is around 5.0 – 6.0, during maturation, the pH value decreases and reaches the 
threshold pH (5.0 – 5.7) for HA mediated membrane fusion (139).  Low pH triggers a 
conformation change of the activated HA trimer for membrane fusion (65). 
Simultaneously, influx of protons (H+) from the endosome via the M2 ion channel 
acidifies the interior of influenza particles which disrupt protein-protein interactions 
and release the vRNPs from other viral components (140, 141). This strict pH 
requirement controls the precise timing for vRNPs release. The released vRNPs are 
further translocated to the nucleus for replication and transcription to continue the 
viral life cycle.  
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Figure 1.5. Influenza mediated membrane fusion 
 
 
 
 
 
  
 
 
 
 
Adapted from Cross KJ, Burleigh LM & Steinhauer DA, Expert Reviews in Molecular 
Medicine,3, 1 (2001) (142) 
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1.4.3 Hemagglutinin Activation 
HA activation is an essential step for influenza infection as it allows release of 
the fusion peptide from HA and hence, initiates downstream reactions that were 
covered at section 1.4.2 “membrane fusion”. In most cases, HA activation takes place 
in the extracellular matrix or on the cell surface, in the case of HPAI, HA activation by 
furin takes place in the trans-Golgi network (TGN) during viral assembly (143-145). 
Activation of HA involves a one-step proteolytic cleavage at the HA cleavage site 
located at the junction between the HA1 and HA2 domain by host, and sometimes, 
bacterial proteases. Although HA cleavage sites vary between subtypes, the P1 
position (the first amino acid at the N-terminus of the cleavage site) is conserved with 
an Arg residue among all subtypes with a few exceptions that include a Lys at P1. A 
monobasic cleavage site is defined by the presence of single Arg at P1 and is 
cleaved by trypsin-like serine proteases (146, 147). These proteases are distributed 
mainly in the respiratory and/or intestinal tracts, and therefore, such cleavage site 
restricts the tropism of influenza viruses within these tissues. In some rare situations, 
influenza viruses, such as A/WSN/1933 (H1N1), acquire mutations on the HA 
cleavage site and the NA to gain the ability to replicate in the brain by using an 
alternative protease, plasmin (Pm) (92, 148). In extreme cases, highly pathogenic 
avian influenza (HPAI) viruses gain universal tropism by using ubiquitous proteases 
for activation (149). For instance, HPAI H5 HA has a polybasic HA cleavage site 
which contains multiple basic residues Lys or Arg that can be cleaved by ubiquitously 
expressed furin-like proteases (150, 151). Therefore, the protein sequence at the HA 
cleavage site determines which protease is used and subsequently, influence 
influenza tropism and pathogenesis. The sequence variability of the HA cleavage site 
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between subtypes suggest that influenza viruses use a broad spectrum of proteases 
for activation. Since the discovery of HA activation in the late 1970s, the field has 
gained a tremendous amount of knowledge regarding the proteases involved in this 
critical step. 
1.5 Serine Proteases 
1.5.1 Serine proteases overview 
Serine proteases consist of almost one-third of all proteases that have been 
identified and a subset of the family of proteins is able to activate influenza HA. The 
active site of serine proteases consist of a catalytic triad composed of aspartic acid 
(113), histidine (His) and Ser which act as a nucleophile during hydrolysis of the 
targeted peptide bond (152). Catalysis of serine proteases involves four steps, 1) A 
nitrogen on His removes a proton from Ser which initiates the nucleophilic attack on 
the carbon of the peptide bond and forms a tetrahedral intermediate. 2) The electron 
from the peptide bond attacks the proton on His and breaks the peptide bond 
generating the acyl-enzyme intermediate, releasing the N-terminus of the peptide 
(152). 3) A water molecule acts as a nucleophile and attacks the carbon of acyl-
enzyme intermediate, ejecting the C-terminus of the peptide (152, 153). 4) The active 
site is regenerated by re-protonation of the Ser by a hydrogen ion on His which 
originated from water (152).  Despite of the overall similarity of the catalytic process, 
substrate specificities of serine proteases are vastly different. Specificity of substrate 
is measured by the value kcat/Km whereas kcat is mainly determined by the binding 
pocket of each serine proteases (152). The substrate specificity determinants can 
extend from P6 to P3’ (P3’ being the third amino acid at the C-terminus of the 
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cleavage site) of the peptide. Furthermore, there is a dynamic selection process 
between HA cleavage sites and host proteases. Below, we will discuss further some 
of the typical serine proteases that activate influenza HA.   
1.5.2 Trypsin and Factor Xa 
Trypsin and factor Xa are the proteases of choice when culturing influenza 
viruses in vitro. Trypsin is the activated form of trypsinogen which is produced in the 
pancreas and is a very abundant digestive enzyme of the intestinal tract (154). Its 
broad substrate specificity (only requiring a P1 Arg or Lys, except substrates with P1’ 
Proline, Pro or P) and high efficiency allow it to activate most if not all influenza 
viruses in vitro. However, it is not considered to be relevant for human influenza 
infection in vivo due to its localization in the intestinal tract. Factor Xa is a coagulating 
factor in blood that preferably cleaves at the carboxyl side of an Arg in the following 
motif: Ile-(Glu or Asp)-Gly-Arg. It is very abundant in ECE and is responsible for 
activating influenza viruses during virus cultivation in ECE (155). As for trypsin, it is 
considered to be irrelevant in bona fide infection as influenza virus does not get into 
the blood stream typically.   
1.5.3 Tryptase Clara and Mini-plasmin 
Tryptase Clara and mini-plasmin were isolated from the supernatant and the 
membrane fraction of rat lung tissue respectively and were shown to activate 
influenza HA (H3N2) (156, 157). Tryptase Clara is a soluble protease secreted by 
non-ciliated secretory Clara cells found in the bronchial epithelia. Tryptase Clara 
cleaves at the carboxyl side of Arg found in the protease’s preferred cleavage site, 
Gln-Ala-Arg. Mini-plasmin is found on epithelial cells in the upper divisions of 
bronchioles (158). Unlike tryptase Clara, it is a hydrophobic protein and is mainly cell 
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associated. Its preferred substrate is Glu-Lys-Lys which is not typical for most 
influenza cleavage sites that typically have Arg at the P1 position. Nevertheless, both 
mini-plasmin and tryptase Clara are considered to play an important role in influenza 
activation in vivo.     
1.5.4 Type II transmembrane serine proteases (TTSPs) 
Before the establishment of human adenoid epithelial cell (HAEC), studies of 
HA cleavage in vitro mainly relied on permanent cell lines. HAEC demonstrated 
multiple physiological hallmarks of actual upper respiratory tract cells and is 
considered to be an adequate model for natural infection. Studies on HAEC shows 
that HA activation is largely cell associated, suggesting an important role of 
membrane bound proteases (143). TTSPs are serine protease involved in 
homeostasis and development, currently, there are seventeen indentified members in 
humans and four of them, TMPRSS2, TMPRSS4, TMPRSS13 and human airway 
trypsin like protease (HAT or TMPRSS11D), have been shown to activate HA (159-
162). All four of them have been detected on the cell surface along the upper 
respiratory tract and many other epithelia, suggesting a role in in vivo HA activation. 
TMPRSS2 and HAT are able to activate all HAs that have been tested (H1 – H16) 
with variable efficiency (161). TMPRSS4 has been shown to cleave the 1918 
pandemic HA whereas TMPRSS13 can cleave tetra-basic HA cleavage sites (162). 
To our knowledge, the biochemical properties of TTSPs have not been systemically 
studied yet, and substrate specificities of individual members are largely unknown. 
1.5.5 Plasmin (Plg) and Plasminogen (Pm) 
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Plg is produced in the liver as a zymogen by folding in a closed conformation 
and is very abundant in the plasma (2 M) (163). Plg is a 81 kDa protein separated 
into 2 domains: structural kingle domain and the protease domain (164). The cellular 
function of Pm is to degrade fibrin in blood clot by fibrinolysis. Activation of Plg to Pm 
requires tissue plasminogen activator (tPA) and/or urokinase plasminogen activator 
(uPA) (165, 166). Both PAs are serine proteases which cleave between Arg561 and 
Val562 of Plg and release the protease domain as Pm. Soluble Pm is readily 
inactivated by 2-antiplasmin and 2-macroglobulin which are very abundant in 
plasmin (167). Functional Pm is the first protease shown to activate influenza HA, 
with its preference for substrates with an aromatic residue at the P2 position, such as 
Tyr, Phe and Trp. WSN is a mouse adapted influenza virus with a P2 Tyr at the 
cleavage site and was shown to use Pm extensively (148). Along with an additional 
mutation on NA that recruits Plg, WSN is able switch tropism and replicate in the 
brain in a NA dependent manner (92).        
1.5.6 Furin 
Furin belongs to the subtilisin type of serine proteases and is a member of 
proprotein convertase family (PC) (168). Furin is ubiquitous expressed in humans and 
is mainly located in the trans-golgi network (TGN) inside cells (169). The binding 
pocket of furin is highly acidic (negatively charged) and thus prefers substrates that 
are highly basic. As such, the optimal cleavage site for furin is Arg/Lys-X-Lys-Arg/Lys. 
In normal circumstance, furin does not activate influenza HA; however, it specifically 
activates the polybasic cleavage site of HPAI and therefore, allows the virus be 
activated systemically within the body (151).   
1.5.7 Miscellaneous Proteases 
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Other serine proteases have also been identified to have proteolytic activities 
on influenza HA, including matriptase, kallikrein 5 (KLK5), kallikrein12 (KLK12) (170, 
171). Interestingly, some of them show subtype specificity, supporting the idea that 
each influenza virus might have its own preference for a particular protease. For 
instance, KLK5 is able to cleave H1 and H3 efficiently, while KLK12 prefers H1 and 
H2 subtype. Activation of HA is not limited to eukaryotic proteases, some bacterial 
proteases or co-factors can activate HA directly and indirectly. A 43 kDa protein 
isolated from Staphylococcus aureus supernatants was shown to activated HA 
directly (172). Streptokinase A (ska) and staphylokinase (sak) from Streptococcus sp. 
and Staphylococcus sp. respectively, are able to cleave HA via activation of host Plg 
(173). The three-way interactions between host, bacteria and virus suggest a novel 
synergistic mechanism by influenza and bacterial co-infections.    
1.6 Bacterial Co-Infections with Influenza 
Bacterial co-infections and secondary infections with influenza has been 
shown to associate with disease complication and death (174). The bacterial agents 
implicated in disease progression includes Staphylococcus aureus, Group A 
Streptococcus (155), Streptococcus pneumoniae and Haemophilus influenza (174). 
However, the synergy between bacteria and influenza are multidirectional and multi-
faceted and are largely unknown. Although a comprehensive mechanism of the 
relationship is unclear, current studies provide convincing evidence on different 
aspects. So far, the hypothesis of bacterial-influenza synergy mainly includes three 
areas: a) Immune-modulation by the pathogens, b) Influenza priming bacterial 
infection and c) bacterial enhancement of influenza virus pathogenesis (175). 
1.6.1 Immune Modulation 
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 When bacteria or viruses infect a cell, they both elicit similar pro-inflammatory 
responses by inducing IL1, IL4 and TNF- production. However, during dual 
infections, the combined effects result in an elevation of pro and anti-inflammatory 
responses which lead to dysregulation of the immune system. Accumulation of non-
functional neutrophils results in influx of inflammatory cells into the site of infection 
(176). On the other hand, a pro-apoptotic protein PB1-F2, which is encoded in some 
strains of influenza, is associated with increased in virulence of the virus in bacterial 
co-infection setting (177). In a mouse model study, PB1-F2 induces pro-inflammatory 
cytokines and an influx of neutrophils into the lungs which impairs the host ability to 
kill bacteria (118). 
1.6.2 Influenza Virus Infection as a Primer to Bacterial Infection 
Viruses are able to prime host tissue and turn them into a favorable 
environment for bacterial attachment and colonization. Ciliated cells serve as a 
physical barrier to prevent easy penetration of pathogens into the respiratory tract by 
the beating motion of cilia. The beating motion is decreased during influenza infection 
which facilitate bacterial invasion of the respiratory tract (178). Influenza infection also 
induces epithelial damage, exposing the basal layer of cells for bacterial attachment 
and colonization (179). Influenza proteins can also directly modify otherwise non-
functional bacterial receptors. In influenza infected MDCK cells, viral NA removes the 
glycan of an unknown receptor which is otherwise inaccessible to S. pneumoniae, 
therefore enhances the binding of the bacteria to host cells (180). Another pathogen 
GAS, also attaches to influenza-infected MDCK cells. This attachment relies on the 
viral HA and the presence of fibronectin (181, 182). 
1.6.3  Bacteria Priming Influenza Infection 
 30 
 
In a mouse model study, an increase of influenza viral titers is observed in S. 
pneumoniae co-infection. The result suggests that influenza replicates better in the 
presences of S. pneumoniae (183). Other studies have also shown that patients 
suffering from bacterial-influenza co-infection require a prolonged phase for recovery 
than patients with a sequential bacterial infection after influenza infection (184). 
Together, these studies suggest that bacteria enhance and prolong viral infection 
duration by some unknown mechanisms. One hypothesis is that bacterial co-infection 
with influenza virus infection allow the virus to access blood circulation and spread 
systemically within the body. For example, a study shows when Escherichia coli is 
inoculated intratracheally along with H9N2 LPAI, the virus can spread to different 
parts of the body (185). However, information regarding the systemic spread of 
influenza virus remains poorly defined. Previous studies have shown that viral RNA 
was presence in the kidney and liver of MS96 infected farm chicken, suggesting that 
the virus is able to disseminate to other organs.  Bacteria have been shown to directly 
enhance pathogenesis of influenza virus. Influenza virus requires proteolytic cleavage 
on its’ HA to become infectious. S. aureus has been shown to secrete a protease for 
this activation event (172, 186). 
1.7 HA Cleavage and Implications 
 The HA cleavage site not only determine the activation state of influenza 
viruses, but also play a significant role in viral tropism and pathogenesis. In 2013, 
there are approximately 650,000 HA sequences that are found on online databases, 
for all of the 18 HA subtypes; each subtype has its signature HA cleavage site and 
there are a myriad of variations for each. Better understanding of the biochemical 
properties of these cleavage sites will lead to knowledge of viral pathogenesis and 
better pandemic planning for potentially highly pathogenic influenza viruses infecting 
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humans. Furthermore, the possibility of uncovering subtype specific proteases would 
allow for the development of a targeted approach for therapeutics using inhibitors for 
specific proteases. In this thesis, I will present three interrelated research work 
projects aiming to dissect the molecular mechanism of this long discovered, yet still 
overlooked issue, influenza activation.        
1.8 Thesis Overview 
 The object of this thesis is to understand the structure and function 
relationship of influenza HA cleavage site and its influence on viral pathogenesis. 
Chapter 2 begins with characterization of a single Ser to Tyr mutation, at the primary 
amino acid structure level, in the HA cleavage site of the 2009 H1N1 pandemic virus. 
This chapter further develops a novel mechanism of influenza virus using an 
alternative protease, Pm for HA activation. The chapter concludes with the finding 
that bacterial co-infection modulates influenza virulence in vivo. Chapter 3 describes 
how a combination of primary and tertiary structure on influenza HA modulates HA 
activation. A loss in sugar moiety and a tri-basic cleavage site converts a LPAI H9N2 
to gain universal HA activation by furin in vitro, a hallmark property of HPAI. The 
finding in chapter 3 also suggests a different evolutionary pathway of H9 HA that set it 
apart from H5 and H7. Chapter 4 demonstrates the same Ser to Tyr mutation on AIV 
which uses a unique mechanism for HA activation.  Chapter 5 summarizes the result 
and discusses future directions on research on HA activation. Chapter 6 is the overall 
material and method section in this thesis. Appendix 1 and 2 describe the baculovirus 
expression system and immune plaque assay respectively.
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CHAPTER 2 
PLASMIN-MEDIATED ACTIVATION OF PANDEMIC H1N1 INFLUENZA VIRUS 
HEMAGGLUTININ INDEPENDENT OF THE VIRAL NEURAMINIDASE 
Abstract 
Influenza virus is well recognized to modulate host tropism and pathogenesis 
based on mutations in the proteolytic cleavage site of the viral hemagglutinin (HA), 
which activates HA and exposes the fusion peptide for membrane fusion. Instead of 
the conventional trypsin-mediated cleavage event, modification of the cleavage site 
allows for extended use of host cell proteases and enhanced spread in vivo. For 
H1N1 influenza viruses, the mouse-adapted A/WSN/33 strain is known to replicate in 
the brain based on recruitment of plasminogen by the viral neuraminidase (NA), as 
well as a Ser-Tyr substitution at the P2 position of the HA cleavage site. Here, we 
show that an equivalent Ser-Tyr substitution has occurred in the HA of naturally 
occurring human H1N1 influenza viruses. We characterize one of these viruses 
(A/Beijing/718/2009), as well as the prototype A/California/04/2009 with a Ser-Tyr 
substitution in the cleavage site, and show that these HAs are preferentially cleaved 
by plasmin. Importantly, cleavage-activation by plasmin/plasminogen was 
independent of the viral NA, suggesting a novel mechanism for HA cleavage 
activation. We show that the viral HA itself can recruit plasminogen for HA cleavage. 
We further show that cellular factors, as well as streptokinase from bacteria 
commonly co-infecting the respiratory tract of influenza patients, can be a source of 
activated plasminogen for plasmin-mediated cleavage of influenza HAs that contain a 
Ser-Tyr substitution in the cleavage site. 
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2.1 Introduction 
Influenza virus remains a major cause of morbidity and mortality in the human 
population (187), with the ever-present risk of new pandemics arising—especially as 
emerging viruses from zoonotic transmission events. The influenza virus 
hemagglutinin (HA) mediates both receptor binding and membrane fusion during 
virus entry (188). A key step in activation of HA is its cleavage by host cell proteases 
(147, 150, 189), where proteolytic cleavage activation is directly related to exposure 
of the fusion peptide (190). Low pathogenicity influenza virus strains contain a HA 
cleavage site with a single arginine residue, and are thus described as having 
monobasic cleavage sites. These viruses can utilize trypsin (or other trypsin-like 
serine proteases) for activation, with the tissue distribution of the activating protease 
typically restricting infection to the respiratory and/or intestinal organs (149). In the 
case of highly pathogenic avian influenza viruses (HPAIs) such as H5N1 and H7N7, it 
is well established that mutations in the region of the HA cleavage site lead to an 
insertion of several arginine or lysine residues in addition to the cleavage site 
arginine. Such HAs can be recognized by furin or related intracellular serine 
proteases found in many cell types, allowing a widening of the cell tropism of the virus 
(151). The presence of a polybasic cleavage site is critical for the systemic spread 
and increased virulence associated with HPAI. 
Influenza A viruses exist as many different subtypes (H1-H17), with H1 and 
H3 viruses currently infecting humans and H1N1 viruses responsible for the 2009 
influenza pandemic (187, 191). With the exception of the 1918 influenza virus, H1 
viruses are considered to have low pathogenicity and as such have a monobasic 
cleavage site. However, two H1 isolates A/WSN/33 (WSN) and A/NWS/33 (NWS) 
have been selected to propagate in mouse brain, and are thus considered to be 
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highly pathogenic, neurovirulent viruses in mice (192, 193). The A/WSN/33 virus in 
particular has been used extensively for studies on influenza replication and 
pathogenesis, in part because this virus forms plaques in the absence of trypsin and 
serves as a model of highly pathogenic influenza virus. The HA of the A/WSN/33 
virus was originally shown to be cleaved by plasmin, following activation of serum 
plasminogen in MDBK cells (194). The virulence properties of A/WSN/33 were 
subsequently linked to the neuraminidase (NA) gene (195) and the absence of a 
glycosylation site at position 130 of NA (94). In addition, the presence of a C-terminal 
lysine on NA was shown to be critical for the virulence properties of A/WSN/33, with 
the viral NA binding and sequestering plasminogen on the cell surface, leading to 
increased cleavage of HA (92, 196). Nayak and colleagues originally suggested that 
plasmin-mediated cleavage of A/WSN/33 HA may be influenced by residues 
neighboring the HA cleavage site arginine (197), and we have recently determined 
that a mutation in the HA cleavage site of A/WSN/33 is important for plasmin-
mediated cleavage and neurovirulence (148). This is a Ser-Tyr substitution at the P2 
cleavage site position, adjacent to the P1 cleavage site Arg. HA cleavage data is 
consistent with biochemical data showing that bulky hydrophobic residues in the P2 
position of substrates strongly promote their plasmin-mediated cleavage (198-200). 
While A/WSN/33 represents a specific and highly-laboratory adapted form of 
influenza virus, ongoing influenza surveillance studies have shown that an equivalent 
Ser-Tyr substitution in the P2 cleavage site position of HA has also occurred in 
certain naturally occurring influenza viruses. Here, we studied the cleavage activation 
of the HA of one of these naturally occurring influenza viruses (A/Beijing/718/09), as 
well as the prototype A/California/04/09 H1N1 virus with a Ser-Tyr substitution in the 
P2 cleavage site position of HA. We show that the presence of a P2 Tyr markedly 
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enhances plasmin-mediated cleavage of naturally occurring influenza viruses. 
Significantly, plasmin-mediated cleavage activation occurs independent of the viral 
neuraminidase, and so represents a distinct mechanism for enhanced cleavage 
activation of HA in vivo. 
2.2 Results 
2.2.1 Bioinformatics analysis of the influenza virus H1 cleavage site 
A multiple sequence alignment of the HA genes of representative H1 influenza 
viruses reveals an invariant Arg at position 329 (numbering based on H3 subtype 
virus A/Aichi/2/68), which comprises the P1 position of the proteolytic cleavage site 
(Fig. 2.1A). In addition to the invariant Arg at the cleavage site, H1 influenza viruses 
usually contain a highly conserved Ser at position 328 (the P2 cleavage position). 
A/WSN/33 is an exception to the consensus cleavage site, containing Tyr at position 
328. The HAs of A/Beijing/718/2009 (NCBI accession # ACZ98546) and 
A/Beijing/720/2009 (NCBI accession # ACZ98560) also represent exceptions to the 
consensus cleavage site, as they also contain a Tyr at position 328. 
A/Beijing/718/2009 and A/Beijing/720/2009 were sequenced from human nasal 
swabs, as part of an outbreak of pandemic influenza in Beijing, China in November 
2009. No other information on these viruses is currently available. Additional viruses 
also contain an equivalent substitution (see Discussion) (Fig. 2.1B) 
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Figure 2.1. Multiple sequence alignment of the influenza H1 HA cleavage site 
and fusion peptide. (A) A total of 4325 H1N1 HA amino acid (aa) sequences of 
H1N1 from the NCBI Influenza Virus Resource 
(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) were aligned using muscle 
v3.8.31, and the aligned sequences of representative viruses at the HA cleavage site 
are shown, along with the consensus sequence.  Dots represent identical residues, 
P6 – P1’ positions of the cleavage site and the location of the fusion peptide are 
shown. The representative strains selected are the following: A/ South 
Carolina/1/1918 (accession number AAD17229), A/Puerto Rico/8/1934 (ABO21709), 
A/Wilson-Smith/1933 (ABD77796), A/New Caledonia/20/1999 (ABF21272), 
A/California/04/2009 (ACP41105), A/WSN/33 (AAA43209), A/Beijing/718/2009 
(ACZ98546) and A/Beijing/720/2009 (ACZ98560). (B) List of H1 viruses with serine 
(S) to tyrosine (Y) mutation at the P2 position of the cleavage site, along with the 
information on subtype, accession number and species of isolation.  
 37 
 
 
 
  
 38 
 
2.2.2 Cleavage activation of A/Beijing/718/2009 HA by plasmin 
Based on the prediction that the presence of a Tyr at the P2 cleavage site 
position would increase HA cleavability by plasmin, we examined HA cleavage for the 
A/Beijing/718/2009 HA. An influenza A/Beijing/718/2009 HA gene was synthesized 
based on the database sequence. We compared this HA to a consensus 
A/California/04/09 HA, as well as the A/Beijing/718/2009 HA with a mutation of Tyr-
Ser to match the H1N1 consensus. HAs were expressed in 293T cells and surface 
biotinylation was performed. Cells were then treated with human plasmin and HA 
detected by Western blot to assess the efficiency of plasmin-mediated cleavage. 
Around 32% of the wild type A/Beijing/718/2009 HA was cleaved by plasmin after 60 
min (Fig. 2.2). In contrast, A/Beijing/718/2009 (Y328S) HA showed approximately four 
times less cleavage by plasmin (Fig. 2.2).  
As a control, we also mutated the A/California/04/09 HA, to replace the P2 Ser  
to Tyr. Similar to Beijing/718/2009 HA, the Ser-Tyr mutation at the P2 position of 
A/California/04/09 HA significantly increased HA cleavage by plasmin (Fig. 2.3). The 
higher level of HA cleavage in A/Beijing/718/2009 (codon optimized) than 
A/California/04/09 (non-codon-optimized) likely correlates to the differences in 
expression level. 
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Figure 2.2. Cleavage of the HA of A/Beijing/718/2009 influenza HAs by human 
plasmin. (A) Human plasmin-dependent HA cleavage of A/Beijing/718/2009 (Bei718) 
HA and Bei718 HA-328S. Surface biotinylation was performed on 293T cell 
expressing each HA. Transfected cells were treated with human plasmin (100 mU/ml) 
at the indicated time and cleavage product(s) were detected by western blot using 
anti-HA antibody. (B) Quantification of the time-dependent human plasmin mediated 
HA cleavage efficiency of Bei718 HA and Bei718 HA-328S. The error bars represent 
the standard deviation of three independent experiments. Statistics were performed 
using a Student’s t-test (unpaired, one-tail) by GraphPad Prism, comparing each 
individual treatment time (* p<0.05, ** p<0.005, *** p<0.0001). 
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Figure 2.3. Cleavage of the HA of A/California/04/2009 influenza HAs by human 
plasmin. (A) Human plasmin-dependent HA cleavage of A/California/04/09 (CA0409) 
HA and CA0409 HA-328Y. Surface biotinylation was performed on 293T cell 
expressing each HA. Transfected cells were treated with human plasmin (100 mU/ml) 
at the indicated time and cleavage product(s) were detected by western blot using 
anti-HA antibody. (B) Quantification of the time-dependent human plasmin mediated 
HA cleavage efficiency of CA0409 HA and CA0409 HA-328Y. The error bars 
represent the standard deviation of three independent experiments. Statistics were 
performed using a Student’s t-test (unpaired, one-tail) by GraphPad Prism, comparing 
each individual treatment time (* p<0.05, ** p<0.005, *** p<0.0001). 
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2.2.3 Rescue of plasmin-activation H1N1 infection by introduction of Tyr at the 
P2 cleavage site position 
To determine whether the presence of Tyr at the P2 cleavage site position can 
rescue plasmin-mediated infection of pandemic H1N1 influenza, we introduced a 
S328Y mutation into the A/California/04/09 HA and rescued both wild type and 
mutant recombinant viruses by reverse genetics and growth in embryonated chicken 
eggs. Despite efforts, rescue of the intact A/Beijing/718/2009 HA on a 
A/California/04/09 background was unsuccessful. The introduction of the S328Y 
mutation into the A/California/04/09 HA resulted in increasing levels of plasmin-
mediated cleavage as for A/Beijing/718/2009 (Fig 3). Whereas the wild type 
A/California/04/09 formed plaques on MDCK cells after addition of exogenous trypsin, 
addition of plasmin failed to rescue plaque formation (Fig. 2.4A). In contrast, the 
A/California/04/09 HA S328Y mutant readily formed plaques in the presence of 
plasmin, as well as with trypsin (Fig. 2.4A). Plasmin-dependent plaque formation, but 
not trypsin-dependent plaque formation, was inhibited by the plasmin inhibitor 6-
aminohexanoic acid (6-AHA). Interestingly, addition of serum alone did not rescue 
plaque formation for A/California/04/09 HA-S328Y, in contrast to the situation with 
A/WSN/33 (92, 196) (not shown). In addition to rescuing efficient plaque formation, 
the majority of plaques formed in the presence of plasmin were significantly bigger for 
the Y328 mutant, compared to wild type A/California/04/09 (Fig. 2.4B). 
  
 44 
 
Figure 2.4. Plaque forming properties of recombinant virus on MDCK cells. 
Representative picture of immuno-plaque assay of A/California/04/2009 (rCA0409) 
(A) and rCA0409 HA-328Y (B) virus on MDCK cells. Plaque assays were performed 
by inoculating 30–40 pfu virus on MDCK cells in the presence of TPCK-trypsin (1 
g/ml), human plasmin (h-Pm) (3 mU/ml), 5% FBS or mock treated with or without 
addition of 6-AHA (5 mg/ml) for 3 days. Cells were fixed and viral NP were stained 
with mouse -NP Ab. Secondary -mouse Ab conjugated with Alkaline phosphotase 
(AP) was used to detect virally infected cell clumps visually. Images were taken using 
an Alpha DigiDocTM AD-1200 imager. At least three individual experiments were 
performed for each condition. 
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2.2.4 Effects of introduction of Tyr at the P2 cleavage site position in a mouse 
model of H1N1 influenza 
To investigate the effects of introducing a Tyr at the P2 cleavage site position 
of HA, we challenged mice with the A/California/04/09 and the A/California/04/09 HA-
S328Y mutant via both intra-nasal and intra-cranial routes of inoculation. Mice were 
first challenged intranasally, and samples of lung, trachea, kidney, spleen and brain 
taken at 3 or 6 days post infection. Tissue samples were then assayed for the 
presence of virus by plaque assay in MDCK cells. Both A/California/04/09 and 
A/California/04/09 HA-S328Y replicated well in the lung, and to a limited extent in the 
trachea, with no discernible differences between the wild type and mutant viruses 
(Fig. 2.5A). There was no evidence for spread to the kidney, spleen and brain in 
either case (Fig. 2.5A). Mice inoculated with viruses lost about 15% of weight at the 
end of experiment with no mortality observed, indicated limited pathogenesis in 
mouse. However, there is no difference on weight loss between the 
A/California/04/09 and A/California/04/09 HA-328Y (Fig. 2.5B). 
We also challenged mice intracranially, with brain samples taken at 3 days 
post infection, and assayed for the presence of virus by plaque assay in MDCK cells. 
A/WSN/33 was included as a control for these experiments. While A/WSN/33 
replicated in the brain, there was no evidence for replication of either 
A/California/04/09 or A/California/04/09 HA-S328Y after intracranial inoculation (Fig. 
2.5A). Only A/WSN/33 infected mice showed limited sign of infection with 5% of 
weight loss at the end of experiment. In contrast, A/California/04/09 and 
A/California/04/09 HA-328Y showed no sign of infection and no weight loss as the 
ASCF control (Fig. 2.5C). 
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Figure 2.5.  Mouse model of viral pathogenesis following intranasal and 
intracranial inoculation. (A) Summary of viral titer after 3 days or 6 days post-
intranasal inoculation and 3 days post-intracranial inoculation. Values inside the 
parentheses indicate the portion of positive samples for viral detection in each group. 
Average titers were calculated based on positive samples and were represented as 
log10 pfu/g of tissue. The sign, <, represents viral titer below the detection limit (i.e. 20 
pfu/ml). (B) Percentage of initial weight loss of mice. Mouse body weights were 
measured every 24 hr for intranasal inoculation or (C) every 12 hr for intracranial 
inoculation. Body weights were normalized to the initial body weight prior to viral 
inoculation.  
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2.2.5 Role of the viral neuraminidase on cleavage activation of 
A/Beijing/718/2009 HA 
It is well established for the neurotropic mouse-adapted influenza virus 
A/WSN/33 that the viral neuraminidase (NA) plays a major role in recruiting the 
plasminogen needed for plasmin-mediated HA activation. To assess the role of the 
NA in the context of A/Beijing/718/2009, we examined the effect of co-expression of 
A/California/04/2009 NA on HA cleavage. A/California/04/2009 NA was chosen 
because of its high sequence identity to A/Beijing/718/2009 NA (2 mutations, V106I 
and N248D, corresponding to N2 subtype). The mutations were not predicted to have 
any effect on plasmingoen recruitment. The NA from A/WSN/33 was used as a 
positive control. These experiments were performed in the presence of plasminogen, 
the inactive precursor of plasmin. As expected, A/WSN/33 NA co-expression resulted 
in a greatly enhanced cleavage of A/Beijing/718/2009 HA (Fig. 2.6). In contrast, co-
expression of A/California/04/2009 NA resulted in very limited cleavage of its cognate 
HA (Fig. 2.6) and was at a level equivalent to that in the absence of any NA 
expression. 
While short term (1h) exposure to plasminogen allowed only minimal or no HA 
cleavage in the presence of A/California/04/2009 NA or vector control, longer-term 
treatment (6h) did result in some degree of HA cleavage. To investigate this further, 
we used conditioned medium from MDCK cells to determine if endogenous plasmin 
activators were present. Media recovered from MDCK cells after 24h of cell growth 
allowed HA cleavage activation in the presence of plasminogen, equivalent to the 
level of cleavage with activated plasmin (Fig. 2.7). It is likely that MDCK cells release 
cellular factors such as tissue plasminogen activator (tPA) or urokinase, that would 
account for the low level of plasminogen-mediated HA activation seen in Fig. 2.6.  
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Figure 2.6. HA cleavage by human plasminogen independent from its cognate 
neuraminidase. (A) Time-dependent human plasminogen mediated cleavage of 
A/Beijing/718/2009 (Bei718) HA and Bei718 HA-328S. Surface biotinylation was 
performed as in Fig. 2.2 by co-transfecting Bei718 HA with vector control, WSN NA or 
CA0409 NA and treated with human plasminogen (6 g/ml) as indicated duration. (B) 
Quantification of three individual experiments. The error bars represent the standard 
deviation of three independent experiments, and statistics were performed as for Fig. 
2.2.   
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Figure 2.7. HA cleavage by conditioned medium from MDCK cells. (A) HA 
cleavage of A/Beijing/718/2009 HA. Plg-MDCK conditioned medium was prepared by 
incubating human plasmin (h-Plg) (5 g/ml) on MDCK cells for 18h. The conditioned 
medium was used to treat HA transfected cell for 30 min. Human plasmin (100 
mU/ml) was used as positive control and MDCK medium alone as negative control. 
(B) Quantification of plasminogen (Plg)-MDCK conditioned medium mediated HA 
cleavage. Relative cleavage efficiencies were calculated for Fig. 2.2. The error bars 
represent the standard deviation of three independent experiments, and statistics 
were performed as for Fig. 2.2. 
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2.2.6 Recruitment of plasminogen by influenza hemagglutinin 
Unlike the situation with A/WSN/33, our data show that H1N1 viruses can 
undergo cleavage activation by the plasmin/plasminogen system in an NA-
independent manner. A similar situation has been reported for the 1918 influenza 
virus, where the viral HA facilitated robust plasminogen binding (159). To determine 
whether an equivalent situation exists for other influenza H1N1 viruses, including 
A/Beijing/718/2009 HA, we tested plasminogen binding of HA using flow cytometry. 
As with A/South Carolina/1/18 HA, the A/Beijing/718/2009 HA bound plasminogen 
(Fig. 2.8). In fact, plasminogen binding was a common property all the HAs tested. 
A/PR/8/34 and A/California/04/09 HA showed the most robust binding (Fig. 2.8), with 
HAs such as A/NWS/33 and A/WS/33 showing less efficient binding. In agreement 
with the findings in Fig. 2.6, A/California/04/2009 NA transfected cells failed to recruit 
any plasminogen as shown by FACS. In these studies, we also included A/WSN/33 
NA, which served as a positive control for plasminogen binding, as well as a mutated 
version of A/WSN/33 NA (R146N, K470; corresponding to N2 subtype), as a 
negative control. Combined, these mutations were shown to abolish plasminogen 
binding (93, 94). 
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Figure 2.8. Plasminogen binding on HA and NA transfected cells by flow 
cytometry. (A) Percentage of human plasminogen binding cell. A/WSN/33 (WSN) NA 
was used as a positive control, pEF4 was used as background binding and WSN NA 
R146N, K470 was used as negative control. CA0409 NA, and eight different H1 
HAs; WSN, A/South Carolina/1/1918 (1918), CA0409, Bei178, A/NWS/1934 (NWS), 
A/Wilson-Smith/1933 (WS), A/Puerto Rico/8/1934 (PR8), A/New Caledonia/20/1999 
(New Caledonia) and one H9 HA (not shown) were tested. The error bars represent 
the standard deviation of three independent experiments. Statistics were performed 
as for Fig. 2.2 by comparing each sample to the negative control. (B) Representative 
FACS traces are shown. Plots were all overlaid with the background control (pEF4 
empty vector) to illustrate the peak shift on x-axis (APC, staining for plasminogen). 
The Y-axis represents the percentage of cell normalized to the maximum cell number 
in a single channel within the plot.   
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2.2.7 Bacterial streptokinase can recruit plasminogen for cleavage activation 
of A/Beijing/718/2009 HA 
As our data clearly indicated that A/Beijing/718/2009 HA was preferentially 
activated by plasmin in an NA-independent manner, we also examined other ways 
that plasminogen could be recruited and activated for HA cleavage. One likely 
possibility is via bacterial virulence factors. Bacterial co-infections are common in 
more severe cases of influenza, with S.aureus, S. pneumoniae, S. pyogenes and H. 
influenzae commonly co-infecting the respiratory tract and contributing to the 
pneumonia often associated with influenza morbidity and mortality (11, 201). Many of 
these bacterial species express virulence factors that can recruit and activate 
plasminogen, including streptokinase and staphylokinase (173). As an example 
virulence factor, we tested the effects of streptokinase from S. pyogenes (202). 
A/Beijing/718/2009 HA, or the Y328S mutant, was expressed on the surface of cells 
and biotinylated. Cells were then exposed to inactive plasminogen (5 g/ml)), 
bacterial streptokinase (5 g/ml), or a combination of both inactive plasminogen and 
bacterial streptokinase, and the cleavability of HA was determined. Cells were 
exposed to trypsin as a positive control, and with media only as a negative control. 
Exposure to a combination of both inactive plasminogen and bacterial streptokinase 
led to significant increases in the cleavage of HA for A/Beijing/718/2009 HA (Fig. 2.9). 
In contrast, treatment with plasminogen and streptokinase led to a much-reduced 
level of HA activation for the Y328S mutant (Fig. 2.9). 
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Figure 2.9. HA cleavage by bacterial streptokinase-activated human 
plasminogen. (A) Surface biotinylation was performed as mentioned above. 293T 
cells transfected with A/Beijing/718/2009 (Bei718) HA or HA-328S mutant were 
treated with different proteases as indicated for 1h. Cleavage products were detected 
by western blot using anti HA antibody. (B) Quantification of the 
streptokinase/plasminogen (Skc-Plg)-dependent HA cleavage efficiency. Cleavage 
efficiencies were calculated. The error bars represent the standard deviation of three 
independent experiments, and statistics were performed as in Fig. 2.2. 
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2.2.8 Secondary infection by Streptococcus pyogenes (NZ131) increase 
weight loss of A/California/04/2009 HA-328Y infected mice 
To test the synergistic effect of CA0409 HA328Y and Streptococcus pyogenes 
in vivo, we developed a mouse model for bacterial secondary infection. Wild type 
CA0409 and CA0409 HA-328Y were inoculated intranasally in mice followed by 
NZ131 inoculation on Day 3 PI. Regardless of NZ131 secondary infection, CA0409 
infected mice show the same magnitude of weight loss (Fig. 2.10a). In contrast, 
CA0409 HA-328Y infection followed by NZ131 secondary infection shows significant 
weight loss in mice whereas CA0409 HA-328Y and NZ131 infection alone did not 
cause any phenotype (Fig. 2.10b). At day 7 post infection, lung, kidney, brain, spleen 
were harvested from each mouse. However, none of the tissue shows presences of 
viruses or bacteria. (Data not shown) 
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Figure 2.10. Body weight loss of mice followed by Streptococcus pyogenes 
(NZ131) secondary infection. (A) Schematic of experimental design. Mice were 
infected on Day 0 with 1x105 pfu intranasally followed by 1x106 cfu of NZ131 on Day 
3. Body weight were measured every 24 hr for 7 days. Tissues, including lung, 
kidney, spleen and brain were harvested on Day 7 PI. (B) Percentage of initial weight 
of mice after intranasal infection with, CA0409, NZ131 and CA0409 + NZ131. (C) 
Percentage of initial weight of mice after intranasal infection with CA0409 HA328Y, 
NZ131 and CA0409 HA-328Y + NZ131. 
A 
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2.3 Discussion 
We show here that plasmin-plasminogen mediated activation of influenza HA 
can be influenced by mutations in the HA cleavage site of circulating virus strains. 
While cleavage activation of influenza mediated by plasmin-plasminogen has been 
established for some time, its importance for virus infection has been restricted to the 
highly laboratory adapted A/WSN/33 strain, which is known to specifically recruit 
plasminogen via the viral NA protein, with a Ser-Tyr mutation in the P2 position of the 
HA cleavage site contributing to efficient HA cleavage and enhanced viral 
pathogenesis. Here we show that an equivalent Ser-Tyr mutation in the HA of a 
circulating human H1N1 strain also contributes to enhanced cleavage by plasmin-
plasminogen, but without recruitment of plasminogen by NA. 
Our study focused on one pandemic H1N1 virus, A/Beijing/718/2009, however 
it should be noted that this is likely not an isolated example of a virus that is 
preferentially activated by plasmin. In addition to the A/Beijing/720/2009 virus from 
the same surveillance site as A/Beijing/718/2009, a pandemic H1N1 virus with a 
cleavage P2 Ser-Tyr substitution was also isolated in a separate surveillance study in 
humans – A/Taiwan/97196/2009 (203), as well as for several H1 viruses in swine 
(see Fig. 2.1B). As with A/Beijing/718/2009, no clinical information is available for 
these viruses.  
In addition to A/WSN/33, a role for plasmin-plasminogen has been reported 
for other influenza strains, with plasminogen activation mediated by the host cellular 
protein annexin II, which is incorporated into the virus particles (56). A role for 
plasmin-plasminogen has also been proposed for the 1918 influenza virus via direct 
binding to the viral HA (159). Our data show that sequestration of plasminogen by HA 
is a common property of distinct viral strains. However, in general, plasminogen 
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binding by HA was less efficient than for the A/WSN/33 NA (not shown). HA-mediated 
binding of plasminogen likely works in concert with cellular factors such as annexin II, 
tPA or urokinase and mutations in the HA cleavage site to promote HA cleavage 
activation.  
One possible cell type where plasminogen is known to be highly active is 
endothelial cells, which are suggested to be important in the “cytokine storms” 
associated with highly pathogenic influenza viruses (204). Both A/California/04/09 
and the Ser-Tyr mutant were able to infect blood microvascular endothelial cells 
(HMVEC-LBI, Lonza), as detected by immuno-fluorescence assays for viral HA and 
NP (not shown). However, experiments to address any increased virus replication in 
endothelial cells based on a Ser-Tyr cleavage site mutation or use of plasmin-
plasminogen failed to show any productive rounds of virus infection as compared to 
A/WSN/33, which appeared to replicate to a limited degree (not shown).  
Although in vitro data shows enhanced usage of plasmin for HA activation with 
Ser-Tyr substitutions at the P2 cleavage site position, data from the mouse model 
shows no discernible differences between A/California/04/09 and A/California/04/09 
HA-328Y. The situation in humans remains unresolved, with the lack of effect in the 
mouse possibly due to differences in the activating protease. This discrepancy could 
be addressed in cell culture models of the human respiratory epithelium. The data 
from intracranial inoculation showing that A/California/04/09 HA-328Y is unable to 
replicate in brain indicates that additional mutations in HA are required for 
neurotropism. Given that bacterial co-infections are common with influenza, and 
based on the data reported here on the role of bacterial streptokinase, one possible 
outcome is that P2 Ser-Tyr substitution is important in the context of a bacterial co-
infection, e.g. with plasminogen-activating S. aureus or S. pyogenes. One possibility 
 59 
 
is that a Ser-Try mutant can be selected in the respiratory tract of a patient with 
ongoing influenza-bacterial co-infection, which would allow extended use of 
proteases such as plasmin.  In the absence of clinical data from humans, it will be 
interesting to test this in mouse models of influenza-bacterial co-infections. 
Despite extensive efforts regarding influenza surveillance, and the large 
amount of sequence information in the database, molecular characterization of 
clinically relevant viruses identified in surveillance studies is still lacking. The 
combination of bioinformatics analysis and experimental virology plays an important 
role is translating the sequence information to a real understanding of the 
heterogeneous viral population. Here, we provide an example of a distinct variant 
human pandemic virus with discrete biological properties, and describe its molecular 
properties both in vitro and in vivo. Such studies can provide important information for 
pandemic planning. 
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CHAPTER 3 
ACTIVATION OF AVIAN INFLUENZA VIRUS H9N2 BY FURIN 
Abstract 
Avian influenza H9N2 is prevalent in waterfowl worldwide and has become 
endemic in poultry in Asia and the Middle East. H9N2 influenza viruses have served 
as a reservoir of internal genes for other influenza viruses that infect humans, and 
several cases of human infections by H9N2 influenza viruses have indicated its threat 
to the human population and pandemic potential. Fortunately, an extensive 
surveillance program enables close monitoring of H9N2 influenza viruses worldwide 
and has generated a large repository of virus sequences and phylogenetic 
information. Despite the large quantity of sequences in different databases, very little 
is known about specific virus isolates and their pathogenesis. Here, we characterize a 
low pathogenicity avian influenza virus (LPAI), A/chicken/Israel/810/2001 (H9N2) 
(Israel810), which is representative of influenza virus strains that have caused severe 
morbidity and mortality in poultry farms. We show that under certain circumstances, 
the Israel810 virus can be activated by furin, a hallmark of highly pathogenic avian 
influenza virus (HPAI). We demonstrate that Israel810 HA can be cleaved in cells with 
high levels of furin expression, and that a mutation that eliminates a glycosylation site 
in HA1 allows the Israel810 HA to gain universal cleavage in cell culture. 
Pseudoparticles generated from Israel810 HA, or the glycosylation mutant, transduce 
cells efficiently. In contrast introduction of a polybasic site into H9 HA lead to 
pseudoviruses that are comprised for transduction. Our data indicate a mechanism 
for an H9N2 evolutionary pathway that may allows it to gain virulence in a distinct 
manner from H5 and H7 influenza viruses.  
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3.1 Introduction 
Influenza A virus H9N2 was first isolated in the United States in 1966 in 
turkeys (205), and was subsequently found to be prevalent among waterfowl and able 
to spread to poultry worldwide (206-208). H9N2 avian influenza viruses have now 
become endemic in China and the Middle East (207, 209, 210). The impact of H9N2 
influenza is not restricted to the poultry industry and avian species; sporadic cases of 
humans infected by H9N2 have also been reported (21, 211). H9N2 influenza is 
different from H5 and H7 influenzas, where some strains are defined as highly 
pathogenic by the World Organization for Animal Health (212) based in part by the 
presence of multiple basic amino acids in the hemagglutinin (HA) cleavage site (212). 
All of the isolated strains of H9N2 are of low pathogenicity according to the OIE 
classification. Despite this, several outbreaks of H9N2 virus infections have caused 
serious disease, and in some cases a high mortality rate, in domestic poultry farms 
(213-215). Several known reassortment events of H9N2 with H5N1 mean that H9N2 
influenza viruses have the potential to be the donor or acceptor for more virulent 
influenza viruses (22, 216, 217). Furthermore, some H9N2 viruses have similar 
receptor specificity as human influenza (218). Due to the lack of immunity of the 
global human population to H9 viruses, these viruses are of some concern from the 
perspective of pandemic potential for the human population (22, 219).  
The influenza hemagglutinin (HA) is an important pathogenesis determinant of 
the virus and plays a crucial role for infection (65). Influenza HA needs to be 
proteolytically cleaved at a defined cleavage site to enable exposure of the fusion 
peptide during viral entry, which initiates successful infection (190). In most cases, 
influenza HAs have monobasic cleavage site that contains a single arginine (Arg or 
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R) at the P1 cleavage position. Such cleavage sites are typically activated by trypsin-
like serine proteases (150). This requirement restricts the tropism of influenza viruses 
to the types of tissues that express the proteases for activation. In some situations, 
highly pathogenic avian influenza (HPAI) viruses of the H5 and H7 subtypes have 
gained the ability to systemically infect the host by facilitating the activation of their 
HAs. HPAI H5 HAs are mutated to have multiple insertions of basic residues (Arg, R 
or Lys, K) at the cleavage site, to gain a polybasic cleavage site, and to make use of 
more ubiquitously expressed furin-like proteases (150, 151).  
Furin is a member of the proprotein convertase family that is ubiquitously 
expressed (169).  Although furin is expressed universally, expression levels vary and 
can be quite low depending on tissue types (220). Under specific conditions including 
co-infections with other pathogens, furin expression is elevated (221-223). Substrates 
of furin are mostly basic in nature, as determined biochemically by fluorescence 
resonance energy transfer (FRET)-based peptide assays (224). The minimum 
sequence requirement of furin is R-X-X-R, which consists of two paired arginine 
residues at the P1 (cleavage) and P4 position, where X can be any amino acid. 
However the presence of a basic residue at P2 enhances furin cleavage markedly 
(168). Interestingly, the consensus cleavage site of H9N2 influenza virus is predicted 
to be capable of cleavage by furin, with the sequence of R-S-S-R (serine, Ser or S). 
Furthermore, a subset of H9N2 viruses have a mutated cleavage site (R-S-K-R or R-
S-R-R) that is predicted to be more optimized for furin cleavage (225). However, 
several studies have shown that such HA sequences are not efficiently cleaved by 
furin (226, 227). The inconsistency of the biochemical prediction and the actual 
biological data suggests that other factors may play a role in HA cleavage.  
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Influenza HA is a complex protein, folded in a tertiary structure. In this 
situation, accessibility of the cleavage site to proteases becomes as important as the 
primary sequence itself. A notable example of this is the influenza 
A/chicken/Pennsylvania/83 (H5N2) (H5 Penn/83) isolate, which becomes more 
pathogenic after a single mutation at the bottom of the stalk of HA (228).This mutation 
eliminates a glycosylation site, which is in very close proximity to the cleavage site. 
The loss of the bulky sugar moieties is thought to reduce the steric hindrance of the 
protease to the cleavage site; thus, indirectly increasing the accessibility of the 
cleavage site. In addition to the polybasic cleavage site, HPAI H7 HAs contain a 
peptide insert upstream of the HA cleavage site to increase the accessibility of the 
cleavage site to proteases (229).  In other situations (most notably with equine H7N7 
viruses) the addition of 11 amino acids adjacent to the cleavage site allowed 
increased cleavage and fusion activation (171, 230), presumably by repositioning and 
increasing accessibility of the cleavage site motif. The impact of these types of 
modifications for H9 influenza has not been evaluated. 
Here, we use a prototype H9N2 virus with an R-S-K-R cleavage site, and 
which is associated with high mortality in poultry (A/chicken/Israel/810/2001 
[Israel810]). We characterize the possibility of HA activation by furin under different 
expression conditions, and in the context of addition of peptide inserts in the HA 
cleavage site and removal of glycosylation at the base of the HA stalk. In this study, 
we find that furin expression level is directly proportional to the efficiency of HA 
cleavage, with implications for viral spread in the host. We also find that removal of 
glycosylation site 13, a mutation already present in certain H9N2 field strains, leads to 
the efficient activation of A/chicken/Israel/810/2001 by endogenous furin, showing the 
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potential for a defined constellation of mutations that impact HA activation. Our 
studies allow better understanding of the virus at the biological level in the context of 
influenza surveillance data and pandemic preparation.  
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3.2 Results 
3.2.1 Minimum furin cleavage site in H9 HA 
Based on multiple sequence alignment analysis of a total of 2801 sequences 
of H9N2 HA from the Influenza Research Database (FluDB), the consensus 
sequence of the H9N2 cleavage site was determined to be R-S-S-R (Fig. 3.1). 
However, the HA cleavage site of H9 influenza viruses is somewhat variable 
particularly at the P2 position, which has predominant substitutions of lysine (K), 
arginine (R), asparagine (N) and glycine (G). While R-S-S-R constitutes a minimal 
furin cleavage site, it is notable that a substantial number of isolates, (29/2801, or 
1%) have a single Lys (K) substitution at the P2 position of their cleavage site, S321K 
(based on H3 numbering, A/Hong Kong/1968) that is predicted to be a more 
optimized substrate for furin (227). Predictive scores for furin cleavage are shown in 
Fig. 3.1, based on the Pitou 2.0 furin cleavage prediction algorithm (231). Pitou 2.0 
accurately predicts furin cleavage sites by taking into account solvent accessibility 
and binding strength of residues of protein sequences. A sequence with a negative 
score is considered to be unfavorable for furin recognition and cleavage, while a 
positive score is predictive of furin cleavage with higher values being more 
processive. 
Israel810 HA (with R-S-K-R cleavage site) is predicted to be cleaved by furin, 
with the highest score of +9.14 among all the H9 sequences. In comparison, HPAI 
A/Chicken/Hong Kong/220/1997 (H5N1) has a score of +13.59 (Not shown). 
Wisconsin1966 (V-S-S-R) has a negative score, which indicates it is not able to be 
cleaved by furin, and the consensus sequence (R-S-S-R) has a score of +3.72. 
Viruses containing the S321K mutation are clustered in Middle East and are 
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responsible for several outbreaks in local poultry farms infecting a wide range of 
avian species (Fig. 3.1B) (232) . The full list of strains containing the 321K 
substitution, along with their accession numbers, are shown in Fig. 1B. 
A/Israel/810/2003 (H9N2) was selected as a prototype virus representing H9 viruses 
with the 321K substitution within the Middle East.  
  
 67 
Figure 3.1. Multiple sequence alignment of H9 HA. (A) A total of 2801 sequences 
obtained from NCBI Influenza Database 
(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) were aligned by MUSCLE 
alignment program. HA cleavage site from P6 to P1 and fusion peptide are shown. 
H9HA consensus sequence is shown in bold font, underneath it are representative 
strains where sequence differences from the consensus H9HA are indicated as single 
letter amino acid code. Representative strains and their accession number are as 
follow: A/Duck/Hong Kong/W213/1997 (BAG72217), A/Chicken/Hong Kong/G9/1997 
(AAF00701), A/Turkey/Wisconsin/1/1966 (BAA14335), A/Turkey/Israel/810/2001 
(ABS50802), A/Ostrich/Eshkol/1436/2003(AAW29080), A/Quail/Shantou/2061/2000 
(ABM46232), A/Chicken/Israel/786/2001 (ABS50800), A/Turkey/Israel/747/2005 
(ABS50799). Pitou furin prediction score of the representative strains, positive value 
indicates favorable cleavage by furin where the value is proportional to the predicted 
efficiency of cleavage of a given site. (B) Summary of strains harbors the same 
mutation as Israel810. This information was up-to-date during the preparation of the 
manuscript (August 2013). 
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3.2.2 Israel810 HA can be cleaved by furin, but cleavage depends on  
 
furin expression level 
To examine the effect of the 321K substitution in Israel810 HA, a revertant HA 
(321S) with the cleavage site R-S-S-R was generated by site-directed mutagenesis. 
This HA was examined by western blot, along with the WT HA, following cell surface 
biotinylation of 293T cells. Neither HAs were cleaved by an endogenous protease, 
predicted to be furin, in 293T cells (Fig. 3.2A). We hypothesized that endogenous 
levels of furin may be very low in 293T cells, and so not enough for efficient HA 
cleavage. To test this, plasmids containing HA and either human furin (h-furin) or 
chicken furin (ch-furin) were co-transfected in 293T cells. Western blot analysis 
showed that, WT HA was able to be efficiently cleaved by either human or chicken 
furin, whereas the 321S revertant was not (Figs. 3.2B, 3.2C).  Israel810 (WT) HA 
showed 40% and 52% HA cleavage by h-furin and ch-furin respectively.   
3.2.3 Chicken furin has higher processivity than human furin on Israel810 HA 
The above data suggested that chicken furin has a higher processivity than 
human furin in cleaving H9N2 avian influenza HA (Figs. 3.2B, 3.2C). To test this 
observation in a more systematic way, we constructed two tunable expression 
plasmids for ch-furin and h-furin using the ProteoTunerTM Shield Systems (Clontech). 
By fusing the destabilization domain (DD) from the immunophilin FK506-binding 
protein (FKBP) protein to the C-terminus of each furin, overexpressed furin-DD will be 
degraded by default in proteasomes. Furin-DD can be protected by adding Shield 1, a 
stabilizing ligand that binds to the DD and prevent it from degradation. Therefore, 
furin-DD stability can be fine-tuned by addition of different amounts of Shield 1 into 
the transfection mix - as the concentration of Shield 1 will be directly proportional to 
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the level of overexpressed furin in the cell. Furin-DD and Israel810 (WT) HA were co-
transfected into 293T cells supplemented with different concentration of Shield 1 as 
described in materials and methods. Biotinylation and western blot analysis showed 
that HA cleavage is proportional to the concentrations of Shield 1 for both ch-furin 
and h-furin, where ch-furin showed a higher percentage of HA cleavage than h-furin 
(Fig. 3.2D). Quantification of the HA cleavage showed that ch-furin has a higher 
processivity than h-furin on WT HA and was statistically significant at > 500 nM Shield 
1 added (Fig. 3.2E).  
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Figure 3.2. Cleavage of Israel810HA and Israel810HA-321S by endogenous 
proteases, human furin (h-furin) and chicken furin (ch-furin). (A) Representative 
western blot image of HA cleavage by cell surface biotinylation of Israel810HA-WT 
(WT) and Israel810HA-321S (321S) in 293T cells. HA0 and HA2 bands were labeled 
as indicated. Quantification and statistical analysis of HA cleavage from the blot is 
shown on the right. Error bars represent 1 standard deviation (S.D.) from at least 3 
independent experiments.  Data were analyzed by one-tailed Student’s t-test where * 
indicate p<0.05, ** p<0.01 and *** p<0.005. (B) Representative western blots and 
quantification of WT and 321S HA cleavage by transiently co-transfecting HAs and 
plasmids expressing h-furin and (C) cf-furin into 293T cells. Error bars represent 1 
S.D. from at least 3 independent experiments. Statistical analysis and notations were 
same as above. (D) Representative western blot image of surface biotinylation of WT 
HA cleavage by tunable furin expression system in 293T cells. Concentrations of 
Shield 1 were indicated on top of each lane and HA0 and HA2 bands were labeled as 
above. (E) Quantification of HA cleavage of Fig. 3.2D. A curve is fit with each set of 
data with the equation y=10mlogx + c where m is slope and c is y-intercept. Data are 
analyzed by one-tailed Student’s t-test as mentioned above. 
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3.2.4 Analysis of glycosylation sites close to the cleavage site of H9N2 HA 
As furin-mediated cleavage of Israel810 HA was shown to occur, we 
examined possible ways for this process to be more efficient. We first assessed likely 
scenarios for increased cleavage site accessibility via loss of glycosylation. Three 
H9N2 isolates have mutations at the bottom of the stalk region of HA1, which 
accordingly eliminates the consensus, N-X-S/T motif for N-linked glycosylation (Fig. 
3.3A). According to a homology model of Israel810HA generated by Swiss-Model 
(233, 234) and Glyprot (http://www.glycosciences.de/modeling/glyprot/php/main.php), and 
based on the crystal structure of A/Swine/Hong Kong/9/1998 H9N2 (PDB# 1JSD), 
Glycan 13 is very close to the HA cleavage site (Fig. 3.3B). Due to such close 
proximity, this particular glycosylation is likely to affect HA activation by sterically 
hindering protease accessibility to the HA cleavage site. An equivalent mutation was 
found on A/chicken/Pennsylvania/83 (H5N2), and was associated with increasing HA 
activation and thus, pathogenesis of the virus (171, 230). A similar mechanism has 
also been found on mouse-adapted influenza virus, with an increase in virulence of 
the virus (235). To further characterize this mutation in the context of H9 HA, we 
chose to characterize the T15P mutation that was found in two natural isolates, 
A/chicken/Iran/THLBM865/2007 and A/chicken/Guangdong/11/1999. 
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3.2.5 HA cleavage of Israel810HA Glyco13 in 293T cells by endogenous 
protease(s) 
From the previous data, the Israel810 R-S-K-R cleavage site is not able to 
cleave by endogenous furin (see Fig. 3.2A). We predicted that the loss of 
glycosylation site 13 (Glyco13) would likely to enhance HA cleavage. To test the 
hypothesis, two constructs were made and tested following cell surface biotinylation 
of 293T cells. Western blot analysis showed that “Israel810HA  glycosylation 13” 
(WT Glyco13) can be cleaved by endogenous protease(s) in 293T cells, with ca. 
10% of its HA being cleaved which supported our hypothesis. In contrast 321S 
Glyco13 remains intact in its uncleaved form in 293T cells (Fig. 3.3C). Cleavages of 
both Glyco13 HAs are furin dependent, as over-expression of human or chicken 
furin increase the percentage of HA cleavage. WT Glyco13 showed 80% and 90% 
HA cleavage by h-furin and ch-furin respectively, whereas 321S Glyco13 showed 
38% and 50% HA cleavage by h-furin and ch-furin respectively (Fig. 3.3D). In 
general, ch-furin showed slightly higher cleavage efficiency than h-furin on all the HAs 
tested (Figs.3- 2B, 3.2C, 3.3D).  
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Figure 3.3. Glycosylation site 13 affects HA cleavage in Israel810 HA. (A) 
Multiple sequence analysis of H9 HA. Sequence alignment and analysis were done 
as mentioned in Fig. 1A, amino acid 10 – 18 containing an N-linked glycosylation site 
(198) was shown. H9 HA consensus sequence is shown in bold font, underneath are 
three strains where a single mutation eliminate the potential glycosylation site. Strain 
names and their accession number are as follow: A/Chicken/Iran/THLBM865/2007 
(ACY25800), A/Chicken/Guangdong/11/1999 (ACH95446) and 
A/Pheasant/Shantou/4709/2003(ABV48004). (B) Homology modeling of Israel810 HA 
by Swiss-Model based on A/Swine/Hong Kong/9/1998 H9N2 (PDB# 1JSD). Bottom of 
the stem region of HA monomer is illustrated in cartoon form, where HA1 in green, 
HA2 in cyan and fusion peptide in red. The P4 position of HA cleavage site (Arg319) 
is labeled in magenta and glycan (Glyco13) is illustrated as stick in standard CPK 
colors. The closest distance between Arg322 and Glycan13 is determined by PyMol 
as 5.4A. (C) HA cleavage of Israel810HA and Israel810HA-321S with a constellation 
of mutations T15P (Glyco13) by endogenous proteases in 293T cells. 
Representative western blot image of HA cleavage by surface biotinylation of 
Israel810HA-T15P (Glyco13) and Israel810HA-T15P-K321S (321SGlyco13 ) in 
293T cells. HA0 and HA2 bands were labeled as indicated. Quantification and 
statistical analysis of HA cleavage from the blot is shown on the right. Error bars 
represent 1 standard deviation (S.D.) from at least 3 independent experiments.  Data 
were analyzed by one-tailed Student’s t-test where * indicate p<0.05, ** p<0.01 and 
*** p<0.005. (D) Representation western blots and quantification of Glyco13 and 
321S Glyco13 cleavage of transiently co-transfecting HAs and plasmids expressing 
h-furin and cf-furin into 293T cells. Error bars represent 1 S.D. from at least 3 
independent experiments. Statistical analysis and notations were same as Fig. 3.2A. 
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3.2.6 Furin is responsible for cleavage of Israel810 HA 
To confirm that the endogenous protease cleaving HA in 293T cells is furin, an 
siRNA knockdown assay was performed by co-transfecting WT Glyco13 with siRNA 
targeting h-furin (sih-furin). Western blot data showed that sih-furin decreased the 
cleavage level from 13% (mock transfected) and 10% (non-targeting siRNA) to 2%, 
suggesting furin is the cellular factor that is responsible for HA cleavage in 293T cells 
(Figs. 3.4A, 3.4B). 321S Glyco13 was used as a negative control of HA cleavage 
and showed no detectable HA cleavage in all three siRNA treatments (Figs. 3.4A, B). 
Control of knockdown was also examined by Q-RTPCR. The knockdown efficiency 
was ca. 50% when compared to the mock transfected control (Fig. 3.4C). Specificity 
of Q-RTPCR products were monitored in dissociation curves (data not shown) and 
the PCR products were run on 1% agarose gel for confirmation (Fig. 3.4C). 
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Figure 3.4. HA cleavage of WT Glyco13 by endogenous furin in 293T cell. (A) 
Representative western blot image of HA cleavage by surface biotinylation in 293T 
cells. Pools of siRNA targeting h-furin (siFurin1-4), pools of non-targeting siRNA 
(siNon-target) and siRNA re-suspending buffer (simock) were co-transfected with WT 
Glyco13 into 293T cells as described in Material and Methods. (B) Quantification 
and statistical analysis of HA cleavage from Fig. 3.4A. Error bars represent 1 S.D. 
from at least 3 independent experiments. (C) Verification of knockdown effect of furin 
after siRNA treatment. 2-DDCt of human furin and h-GAPDH were determined by 
quantitative reverse transcript polymerase chain reaction (Q-RTPCR) normalized to 
mock treatment. On the right, the cDNAs of h-furin and h-GAPDH from qRT-OCR 
were evaluated on a 1% agarose gel. Error bars represent 1 S.D from 3 different 
experiments.  Statistical analysis and notation are described as Fig. 3.2A. 
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3.2.7 HA pseudovirus particles (PVs) are activated by endogenous furin  
To confirm that HA cleavage results in a functional outcome for infection, a PV 
transduction assay was performed to indirectly quantify HA activation/fusion 
efficiency. PVs with influenza HA and NA on their surface were produced in 293T 
cells, and were used to infect MDCK cells. PV infectivity after different treatments is 
shown as relative light units (RLUs). Trypsin treatment, which activated all the PVs, 
was used as an internal control for the total amount of PV being produced. Fold 
differences between trypsin treatment and no treatment are indicated on top of each 
column pair in Fig. 3.5, and were used as an indirect measurement of HA activation 
efficiency. All the trypsin-treated PVs showed a high RLU value (107) indicating robust 
production and transduction of PVs of all the HAs tested. The no treatment group 
reveals a background level (103), which indicated no or very little activated particles. 
The fold difference of trypsin treated WT Glyco13 is 4,400 times higher than no 
trypsin treatment.  Although there is a 3 log difference for WT Glyco13, it is slightly 
lower than the other 3 groups. The relatively low fold difference of WT Glyco13 HA 
indicates it can be activated by endogenous furin slightly better than the other three 
HAs (Fig. 3.5A).   
3.2.8 HA pseudovirus particles are activated by over-expression of h-furin and 
ch-furin 
To test the functionality of HA activation under over-expression of h-furin and 
ch-furin, the PV infection assay was performed as described above, except that PVs 
were produced in 293T cells transiently transfected with either ch-furin or h-furin. 
Under both conditions, all four PVs are able to show high transduction level (105 – 107 
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RLU) after trypsin treatment, indicating successful production of PV (Figs. 3.5B, 
3.5C). In general, the readings of PVs of the two Glyco13 HAs are about 1 log lower 
than the WT HA. Of all the HAs we have tested, only 321S cannot be activated by 
overexpression of h-furin and ch-furin, reflected by low RLU values (103 – 104). WT 
Glyco13 reveals 105 RLUs regardless of trypsin treatment, indicating all the PVs are 
activated before addition of trypsin. Furthermore, WT HA also shows a very little fold 
difference between trypsin treated or no trypsin treated conditions with 5.6-fold in h-
furin and 14-fold in ch-furin. 321S Glyco13 shows moderate level of activation by h-
furin and ch-furin with 57-fold difference in h-furin and 510-fold in ch-furin.  
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Figure 3.5. Luciferase-based pseudoviral particles (PV) assay of Israel810HA 
and mutants produced in cells expressing either endogenous level or 
overexpressing ch or h-furin. (A) Quantitative HA mediated PV transduction assay 
in MDCK cells. Murine leukemia virus (MLV) based PV with HA and NA on the 
surface were produced in 293T cells described in material and methods. Harvested 
supernatant were either trypsin activated or mock activated before infecting MDCK 
cells. Infections were done in duplicates on MDCK cells for 2 days. Cells were lysed 
and relative light units (RLUs) were measured after addition of luciferin. Fold 
difference between trypsin and non trypsin treatments are shown on top of each 
column pair. Error bars represent 1 S.D. of 3 independent experiments. (B) 
Quantitative HA mediated PV infection assay in 293T cells expressing h-furin and (C) 
ch-furin. PV with HA and NA on the surface were produced in 293T cells 
overexpressing ch-furin and h-furin. Harvested PV was used to infect MDCK cells in 
duplicates and infection was monitored by RLU after addition of luciferin as described 
in Fig. 3.5A. Error bar represents 1 S.D. of 3 independent experiments. Statistical 
analysis was done as mentioned in Fig. 3.2A. 
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3.2.9 HA cleavage in avian cell lines correlates with furin expression level 
H9N2 virus mainly infect avian species. Therefore to examine the cleavage of 
Israel810 HA in cell lines reflecting its natural tropism, we examined the HA activation 
pattern in different avian cell lines. We preformed surface biotinylation using chicken 
fibroblast (DF-1), quail fibroblast (QT-6) and chicken hepatocellular carcinoma (LMH) 
cells. Similar to 293T cells, all of the cell lines support HA cleavage of WT Glyco13. 
QT-6, DF-1 and LMH allow 10%, 55% and 66% of HA cleavage respectively, as 
compared to 10% cleavage in 293T cells (Figs. 3.6A, 3.6B). None of the other three 
HAs were activated in these cell lines (Figs.3- 6A, 3.6B). The mRNA levels of furin 
relative to GAPDH of these avian cell lines were determined by quantitative-RTPCR 
(QRT-PCR) and were normalized to 293T cells. The reported 2-DDCt values show that 
furin mRNA level of DF-1, QT-6 and LMH is 1-, 1.25- and 1.5-fold higher than 293T 
cells respectively (Fig. 3.6C). The cleavage efficiency correlates well with the relative 
mRNA level of furin in these cell lines. 
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Figure 3.6. HA cleavage by 3 different avian cell lines with various levels of 
furin expression. (A) Representative western blot image of HA cleavage by surface 
biotinylation of 3 different cell lines:  Quail embryonic fibroblast (QT-6), chicken 
embryonic fibroblast (DF-1) and chicken primary hepatocellular carcinoma epithelial 
cell (LMH).  (B)  Quantification and statistic analysis of HA cleavage from Fig. 3.6A. 
Error bars represent 1 S.D. from at least 3 independent experiments. Statistical 
analysis and notations were described previously in Fig. 3.2A (C) Q-RTPCR analysis 
of relative expression of ch-furin mRNA to ch-GAPDH of the above cell lines. 2-DDCt of 
ch-furin and ch-GAPDH were determined by Q-RTPCR and is normalized to 293T 
cells as references. Error bars represent 1 S.D from 3 different experiments starting 
from RNA extraction.  Statistical analysis and notation are described as above. 
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3.2.10 Substitution of the H9 cleavage site by HPAI H5 and H7 cleavage sites 
Another possibility for increased HA cleavage is the insertion of additional 
basic residues in the cleavage site, as typified by H5N1 and H7N7 viruses. According 
to all the H9 HA sequences in the influenza database, H9 HAs have not been 
reported to contain any polybasic cleavage sites mimicking H5 or H7 HPAI. To test 
whether H9 HA is able to accommodate such modification, we substituted the original 
H9 cleavage site of Israel810 with H5 and H7 HPAI cleavage sites (Fig. 3.7A). Three 
constructs were made to mimic the H5N1 HPAI polybasic cleavage site (PB), the 11 
amino acid insertion mimicking HPAI H7N3 isolated in British Columbia in 2004 (236) 
with a di-basic cleavage site (Insert+DB) or the same insertion with a tri-basic 
cleavage site (Insert+TB) (Fig. 3.7A).    
Cell surface biotinylation and Western blot reveals that PB, Insert+DB and 
Insert+TB were all able to be cleaved by endogenous furin in 293T cells, in contrast 
to WT HA shown in earlier experiments (Fig. 3.7A). The cleavage efficiency varies on 
different constructs with Insert+TB with 85% being the highest HA cleavage 
efficiency. High efficiencies of HA cleavage, 58% and 56%, were also observed for 
PB and Insert-DB respectively (Figs. 3.7B, 3.7C). A Quantitative PV transduction 
assay was consistent with the biotinylation assays. In general, all constructs were 
able to incorporate into PV as shown in trypsin treated controls. PVs of PB and 
Insert+TB HA were completely activated with only 2.4x and 2.1x fold difference 
regardless of trypsin treatment. Insert+DB was activated by furin very well with only 
180x fold difference between treatments. The small differences between treated and 
untreated sample for all the HAs indicated a trypsin independent activation 
mechanism similar to HPAI (Fig. 3.7D). Overall, the results of the PV assay 
 87 
corresponded very well with the HA cleavage assay very well and demonstrates that 
H9 HA is able to accommodate all modifications found in HPAI. 
3.2.11 H9 HAs with H5 and H7 HPAI cleavage sites affect PV infectivity
 Multiple factors of the envelope glycoprotein including stability, expression 
level, rates of incorporation, receptor binding affinity and fusion activity affect PV 
transduction efficiency. Wild type Israel810 HA and Glyco13 HA PV showed ~107 
RLUs when transducing MDCK cells, indicating similar properties of both HAs at the 
level of virion (Fig. 7E). In contrast, all the PV with H5 and H7 HPAI mimicking HAs 
showed relatively lower readings of ~104-5 RLUs when transducing MDCK cells. 
These drops in transduction efficiency suggest that such PVs infectivity is 
compromised (Fig. 7E) and indicate a decrease in viral fitness when compared to 
Israel810 HA and Glyco13 HA. 
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Figure 3.7. Cleavage and activation of HPAI mimicking H9 mutants by 
endogenous furin. (A) Illustration of four Israel810HA mutants mimicking HPAI virus 
and their cleavage site sequences. Israel810HA WT sequence was illustrated in the 
two long boxes, below are the three HPAI mimicking HAs: Israel810HA-H5 polybasic 
(PB), Israel810HA-H7 insertion plus tre-basic site (Insert+TB) and Israel810HA-H7 
insertion plus di-basic site (Insert+DB). (B) Representative western blot of the HPAI 
mimicking HA by surface biotinylation. (C) Quantification of HA cleavage in Fig. 3.7B. 
Error bars represent 1 S.D. from 3 independent experiments. (D) Quantitative HA 
mediated PV transduction assay of the HPAI mimicking HAs. PV with the HPAI 
mimicking HAs were produced as described in materials and methods. Harvested 
PVs were used to infect MDCK cells and luciferase activities were used as the 
indicator of transduction efficiency and HA mediated membrane fusion. Error bar 
represents 1 S.D. of 3 independent experiments. Statistical analyses and notations 
were done as mentioned in Fig. 3.5A. (E) Summary of RLUs of PV transduction in 
MDCK cells after trypsin treatment. Each value is deduced from their corresponding 
column from Fig. 3.5A and Fig. 3.7D and represents the mean of at least 3 
independent experiments of PV transduction assay. 
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3.3 Discussion 
In this manuscript, we focused on the cleavage activation of 
A/chicken/Israel/810/2001, an avian influenza with a distinct tri-basic cleavage site 
(R-S-K-R) that is predicted to be cleaved by furin, yet is not defined as highly 
pathogenic avian influenza (HPAI). A/chicken/Israel/810/2001 is representative of 
viruses with this cleavage site in an epizootic transmission of influenza in the poultry 
population of Israel between 2001 and 2005 (237). Other H9 viruses with tri-basic 
cleavage sites also meet a similar criteria for furin cleavability without classic HPAI 
definition (e.g. A/quail Shantou/2000 with a R-S-R-R cleavage site), however we 
chose to study A/chicken/Israel/810/2001 as it is representative of a distinct lineage of 
H9 viruses with an identical HA cleavage site (29 sequences isolated in Israel over 
the period 2001 - 2003). In contrast, quail/Shantou-like viruses with a R-S-R-R 
cleavage site have only been isolated very sporadically in the field (two isolations in 
China separated by more than ten years, in 2000 and 2011). In addition, an R-S-K-R 
sequence represents a slightly more optimized furin cleavage motif than R-S-R-R 
(Pitou scores of 9.14 and 8.97 respectively). We find that the HA of 
A/chicken/Israel/810/2001 can be cleaved by furin, with cleavage dependent on the 
Lys (K) residue adjacent to the cleavage site Arg (R). However, the efficiency of HA 
cleavage was only apparent under high furin expression conditions, with cleavage 
directly proportional to furin expression level in the cells. Notably, we find that removal 
of glycosylation site 13, a mutation already present in certain H9N2 field strains (e.g. 
A/chicken/Iran/THLBM865/2007), leads to the efficient activation of 
A/chicken/Israel/810/2001 by endogenous furin, showing the potential for a defined 
constellation of mutations that impact HA activation. Given the geographical proximity 
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in the source of these two virus strains in the Middle East, our data highlight the 
possibility of novel H9 viruses emerging in the field, with increased pathogenicity. 
Previous studies have characterized the cleavage activation of H9 viruses with 
tri-basic vs di-basic cleavage sites (i.e. quail/Shantou) and have shown cleavage of 
HAs with both cleavage site types by human respiratory proteases (matriptase, 
TMPRSS2, HAT), but not by furin (226).  It remains to be determined whether an R-S-
R-R or R-S-K-R sequence is interchangeable from the perspective of furin cleavage 
under over-expression conditions and the ability to integrate with glycosylation site 
changes. The highly similar (although not identical) furin prediction scores for the two 
sequences indicate that both would behave in an equivalent manner. It is unclear why 
viruses with a R-S-K-R cleavage site, compared to R-S-R-R, have been found to 
circulate more widely in nature; this could be due to other changes in HA or other 
genes, or due to poultry production practices in different locations. 
Despite the ubiquitous expression of furin, expression levels vary in different 
cell types, which can be an important determinant for viral infection. As shown for 
infectious bronchitis virus (IBV), the level of furin in cells can be a determining factor 
of their susceptibility to infection (238). Furin levels can also be altered by different 
triggers. Furin promoter can be up-regulated by 3-fold and 400-fold under hypoxia 
and iron depletion conditions, respectively (223, 239), which is similar if not higher to 
the level of expression produced in our experiments. Also, viral infection, including 
H5N1 HPAI, induces a transcription factor, hypoxia-inducible factor 1 (HIF-1), which 
positively regulates expression of multiple genes, including furin (240). Furthermore, 
bacterial infections, such as Staphylococcus sp. (241) and Pseudomonas sp. (242) 
which are prevalent in farmed poultry, can also induce HIF-1 and subsequent furin 
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expression. Such induction may allow an unusually high level of furin to activate HA 
containing R-S-K-R or R-S-S-R cleavage sites that are inert to furin cleavage under 
normal circumstances. This may also explain the higher mortality and morbidity rate 
of H9N2 in farmed poultry than in specific-pathogen-free chickens. The expression 
level of furin also varies among tissues, with kidneys being one of the tissues with 
relatively high expression of furin, and may account for the rare event of H9N2 being 
able to be nephrotropic (243-245). 
Avian influenza viruses are grouped into two main categories: LPAI and HPAI. 
Transition from LPAI to HPAI is thought to be through series of mutations within the 
viral genome. Although some hallmark mutations of HPAI have been characterized 
including a polybasic cleavage site for H5 and a cleavage site insertion of H7, the 
evolution pathway of H9 viruses to become more pathogenic has yet to be fully 
determined. Over the past decade, several H9N2 outbreaks have shown some 
intermediate viruses that are certainly more pathogenic than generic LPAI but below 
the threshold of being HPAI (213-215, 219). These viruses may serve as 
intermediates of the H9 evolutionary pathway, allowing the virus to evolve and 
become more pathogenic. From our data, we show that constellation of mutations 
N15T and S321K, allows HA to be activated by endogenous furin. Our data and other 
previous reports suggest that H9 HA is able to accommodate a polybasic site or an 
11 amino acid insertion and still be functionally cleaved by endogenous furin. 
However, such dramatic changes of H9 HA seem to be deleterious at the level of 
virion. From our pseudovirus transduction assays, we noticed big drops in PV 
infectivity (~ 1 to 2 logs in RLUs) of these HAs compared to the WT Israel810 HA 
which indicate a decrease in viral fitness. This observation may contribute to 
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explaining the puzzling observation that an insertion of a polybasic cleavage site in 
H9 HA that does not convert the virus to HPAI. Our study suggests that a better 
characterization at molecular level of influenza virus would help understand the broad 
spectrum of avian influenza virulence. For instance, introducing terms such as 
moderately pathogenic avian influenza (51) for viruses which are more pathogenic 
than LPAI and show biological features associated with high virulence, but do not 
meet the specific requirements of HPAI set by the OIE. Our studies illustrate that 
some MPAI, especially H9N2 influenza viruses, require a more thorough examination 
than just bioinformatics analysis. 
HPAI is a generalized phenotype determined by series of complex genotypic 
changes in influenza virus. HPAI can arise through different combinations of 
mutations, therefore, it is predicted that a single mutation would not allow the virus to 
become HPAI. As shown by other groups, insertion of a polybasic site in H9 HA is not 
enough to convert the virus from LPAI to HPAI (227, 246). Our results indicate that 
efficient cleavage activation of an H9 HA by endogenous furin can be achieved by a 
combination of a tri-basic cleavage site (R-S-K-R) and a loss of a glycosylation site at 
HA1 residue 13. Each of these features are found individually in nature and our data 
show that the combined changes can be tolerated by the HA protein in terms of 
folding, stability and formation of particles. Whether this mutation combination 
translates into a highly pathogenic virus remains to be tested. Such studies should 
only be carried out under highly prescribed biosafety conditions and with appropriate 
administrative oversight. At present, our work is of importance in the context of 
influenza pandemic planning. 
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CHAPTER 4 
MODIFICATION OF THE HEMAGGLUTININ CLEAVAGE SITE ALLOWS INDIRECT 
ACTIVATION OF AVIAN INFLUENZA VIRUS H9N2 BY BACTERIAL 
STAPHYLOKINASE 
Abstract 
Influenza H9N2 is considered to be a low pathogenicity avian influenza (LPAI) 
virus that is found to infect both chickens and, to a lesser extent, humans. In 1996, 
the influenza virus, A/chicken/Korea/MS96-CE6/1996/H9N2 (MS96) was isolated 
from an outbreak in multiple farms in South Korea that resulted in upwards of 30% 
mortality in infected chickens. Furthermore, the virus was found in a number of organ 
tissues, indicating internal spread of the virus. However, complete recovery of specific 
pathogen free (SPF) chickens occurred after 3 days post infection with the MS96 
virus. We hypothesize that bacterial co-infection may play a significant role in the 
drastic difference in disease progression between farmed and SPF chickens. A key 
determinant of influenza pathogenesis is the susceptibility of the viral hemagglutinin 
(HA) to proteolytic cleavage/activation. Here, we identified that an amino acid 
substitution, Ser to Tyr at the P2 position of the HA cleavage site optimizes cleavage 
by the protease plasmin (Pm). We also identified that certain Staphylococcus sp. are 
able to cleave/activate MS96 HA by activating plasminogen (Plg) to Pm by use of a 
virulence factor, staphylokinase (sak). Overall, these studies provided insight into the 
bacterial mediated enhancement of influenza virus infection and pathogenesis. 
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4.1 Introduction 
Each year, influenza related illnesses cause 250,000 to 500,000 deaths and 
economical loss equivalent to 27 to 87 billion US dollars (9). In rare situations, two or 
more influenza viruses exchange their RNA genomes by antigenic switching and lead 
to emerge of  novel pandemic influenza virus (41). For instance, the 2009 pandemic 
virus arose from quadruple reassortment between birds, pigs and humans influenza 
viruses and caused 71 to 167 billion USD of economical loss (18, 19).  Zoonotic 
transmission of animal influenza to humans is also an important public health 
concern. Avian influenza virus (AIV) is on the top of the zoonotic transmission lists as 
modern human practices in the poultry industry provide an efficient way for close 
contact between humans and poultry. Indeed, increasing cases of humans infected 
by AIV have been reported, including transmission of both highly pathogenic avian 
influenza (HPAI) H5N1 and low pathogenic avian influenza (LPAI) H9N2. 
Furthermore, AIVs were involved in three out of four pandemic influenza outbreaks 
from the last century, indicating the tight link between pandemic and avian influenza 
viruses (67). 
Influenza virus requires activation before infection and activation efficiency is 
an important determinant of viral virulence. The process of virus activation involves 
proteolytic cleavage on the viral envelope protein, hemagglutinin (HA) by host 
proteases. After cleavage, the precursor protein HA0 is separated into HA1 and HA2 
which is a required for successful viral entry. HA1 binds to sialic acid on the surface 
glycoprotein receptor on host cells. After the virus binds to the host surface, it is 
internalized by receptor mediated endocytosis and deposited into the endosomal 
compartment (65). During endosomal maturation, the pH drops inside the endosomal 
lumen, which triggers HA to undergo a conformational change. After the 
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conformational change, the fusion peptide on HA2 extends out and inserts into the 
endosomal membrane. After a series of conformational changes on HA, the 
endosomal and viral membranes merge and allow pore formation to release the viral 
ribonucleoprotein (vRNP) into cytoplasm. The strict requirement of HA cleavage 
restricts influenza infection to the upper respiratory tracts of humans and chickens as 
well as the intestinal tracts of waterfowl whereas specific proteases for HA activation 
are available. Therefore, protease usage for HA activation can also determines 
influenza tropism.  
Proteases for HA activation are not limited to eukaryotic proteases, bacterial 
proteases are also involved in this process. For instance, Staphylococcus sp. and 
Aerococcus viridians secrete soluble proteases that are able to activate HA (173). 
Pseudomonas aeruginosa also indirectly activates HA by activating host proteases 
(173). Furthermore, bacterial streptokinase (skc) and staphylokinase (sak) are also 
able to activate eukaryotic plasminogen into plasmin which can then activate HA 
(194, 247). 
Here, we study the HA cleavage properties of a LPAI AIV A/Korea/MS96-
CE6/1996/H9N2 (MS96), which caused a high mortality rate in farmed chickens. 
MS96 has a Ser to Tyr mutation at the P2 position of the HA cleavage site, an 
equivalent mutation that is found in a neurotropic influenza A/WSN/1933/H1N1 
(WSN). Such a mutation allows WSN to use cellular plasmin for activation. Similarly, 
MS96 HA allows plasmin-mediated HA cleavage, however, different from WSN, the 
activation mechanism of MS96 HA is independent of viral neuramindase (NA). We 
were able to show that MS96 virus uses a different activation mechanism by using 
bacterial sak to indirectly activate HA in the presence of chicken plasminogen (ch-
Plg). A three way interactions between bacteria, the virus and the host potentially 
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explains the discrepancy in clinical outcome between farmed and SPF chickens 
during MS96 infection.  
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4.2 Results 
4.2.1 Variation of P2 position of HA cleavage site in H9 HA 
A multiple sequence alignment of full length influenza H9 HA from the NCBI 
database reveal a consensus HA cleavage site R-S-S-R of H9 HA. (Fig. 4.1A) The 
cleavage site sequence and the first 22 amino acid of the fusion peptide of several 
representative strains of H9N2 viruses are also shown. (Fig. 4.1A) The cleavage site 
of H9HA is highly conserved except the P2 position showing a high variability as 
depicted by Weblogo. (Fig. 4.1B) Viruses containing a P2 substitution are 
summarized, where glycine (Gly, G), aspartic acid (Asp, D) and asparagines (Asn, N) 
are the top three amino acids which replace the consensus P2 serine. (Fig. 4.1C) 
Three particularly interesting strains, chicken/Korea/MS96-CE6/1996 (MS96), 
chicken/Korea/GH2/2007 and ostrich/South Africa/9508103/1995 have a equivalent 
P2 Ser to Tyr mutation resembling the neuro-replicative mouse adapted strain 
A/WSN/1933.  
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Figure 4.1. Bioinformatic analysis of influenza H9N2 HA cleavage site. (A) 
Multiple sequence alignment of full length H9N2 HA from NCBI influenza database 
(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html). A total of 1057 sequences 
were aligned by MUSCLE alignment program. HA Consensus sequence from the P6 
residue of the cleavage site through the first 22 amino acids sequence of the fusion 
peptide are shown in bold. Representative strains are shown underneath the 
consensus whereas differences are shown in single letter amino acid code. 
Accession numbers of the representative strains are as follows: A/duck/Hong 
Kong/W213/1997 (BAG72217), A/chicken/Hong Kong/G9/1997 (AAF00701), 
A/turkey/Wisconsin/1/1966 (BAA14335), A/chicken/South Korea/MS96-CE6/1996 
(ACZ48628), A/chicken/South Korea/GH2/2007 (ADV36582) and A/ostrich/South 
Africa/9508103/1995 (AAQ04843). (B) Amino acids frequency at HA cleavage site. 
Frequencies of each position, from P6 to P3’ of the H9 HA cleavage site are 
illustrated using WebLogo 3.0 (http://weblogo.threeplusone.com/). (C) Summary of P2 
position variation of H9 HA. A numerical summary of the variation in the P2 position 
from 1057 H9N2 strains. 
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4.2.2 Chicken plasmin (ch-Pm) mediated cleavage of MS96 HA 
To determine whether the MS96 HA tyrosine mutation optimizes HA for 
plasmin cleavability, MS96 HA was cloned into a mammalian expression vector and a 
mutant with a single substitution at the P2 position back to consensus serine was 
constructed. Cells expressing MS96 HA or MS96 HA-337S mutant were treated with 
increasing concentration of ch-Pm (100 mU/ml) for 30 min (Materials and Methods). 
Cell surface HA was detected by biotinylation and western blot. Western blot analysis 
reveals that MS96 HA  is efficiently cleaved in a time dependent manner by ch-Pm. 
After 60 min of treatment with ch-Pm, about 15% of MS96HA WT is cleaved. In 
contrast, MS96 HA-337S does not show any significant cleavage with the highest 
being 5% after 60 min of ch-Pm treatment (Figs. 4.3a, b). MS96 HA cleavage by 
trypsin (3 g/ml) is decreased from 50% to 40% compared to MS96 HA-337S 
indicating that a tyrosine residue at position 337Y selects for an alternative protease 
and slightly comprises the use of original protease for activation (Fig. 4.3b). 
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Figure 4.2. Chicken plasmin mediated A/Chicken/MS96-CE6/19966 (MS96) HA 
cleavage is dependent on 337Y. (A) HA cleavage of MS96 HA and MS96 HA-337S 
by ch-Pm. Surface biotinylation was performed on 293T cells expressing each HA. 
Transfected cells were treated with human ch-Pm (5 g/ml) at the indicated time and 
cleavage product(s) were detected by western blot using anti-C9 antibody. (B) 
Quantification of the time-dependent ch-Pm mediated HA cleavage efficiency MS96 
HA and MS96 HA-337S. The error bars represent the standard deviation of three 
independent experiments. Statistics were performed using a Student’s t-test 
(unpaired, one-tail) by GraphPad Prism, comparing each individual treatment time (* 
p<0.05, ** p<0.005, *** p<0.0001). 
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4.2.3 Plasminogen mediated cleavage of MS96HA requires plasminogen 
 
activators 
 
A hallmark of the WSN virus is the additional NA-N146R mutation on the viral 
neuraminidase, which destroys a glycosylation site and allows plasminogen 
recruitment to the viral surface. The recruited plasminogen is then activated into 
plasmin and cleaves HA subsequently with an unknown mechanism which likely to 
involve tissue plasminogen activator (tPA) on the cell surface. To determine if MS96 
NA performs a similar function as WSN NA in recuiting plasminogen and activating its 
cognate HA, cells expressing both MS96 HA and either MS96 NA or WSN NA were 
treated with ch-Plg (5g/ml) for 18h. Biotinylation and western blot analysis shows HA 
cleavage of MS96HA WT only in the presence of WSNNA with about 40% of HA 
cleavage (Figs. 4.3a, b). This result suggests both a P2 tyrosine and a plasminogen 
recruiter are required for HA activation, which is independent of MS96 NA. 
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Figure 4.3. HA cleavage of MS96 HA by chicken plasminogen (ch-Plg) 
independent from its cognate neuraminidase. (A) Representative western blot 
picture of surface biotinylation after co-transfecting MS96 HA with MS96 NA or WSN 
NA in the presence or absence of ch-Plg (5 g/ml) for 18h.  
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4.2.4 The bacterial co-factor staphylokinase (sak) indirectly cleaves MS96HA 
In search of plasminogen recruiter and activator for MS96 HA, we 
hypothesized that an alternative source of activated plasminogen could be produced 
from co-infecting bacteria, either staphylokinase (sak) from Staphylococcus sp. or 
streptokinase (skc) from Streptococcus sp.. Both WT and mutant MS96 HA were 
transfected into 293T cells for surface biotinylation. Ch-Plg (5 g/ml) was incubated 
with sak (10 g/ml) or skc (5 g/ml) for 1 hr at 37oC for activation prior to treatment. 
Transfected cells underwent different treatments as indicated, western blot analysis 
reveals HA cleavage, ~ 35% when MS96 HA is incubated with both ch-Plg and sak. 
No significant HA cleavage was detected from any other treatments. Another 
bacterial plasminogen activator, skc, shows very weak activity on ch-Plg mediated HA 
cleavage. (Data not shown) 
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Figure 4.4. Staphylokinase (sak) from Streptococcus aureus allows ch-Plg 
mediated HA cleavage of MS96 HA. (A) Surface biotinylation was performed as 
mentioned above. 293T cells were transfected with MS96 HA and MS96 HA-337S 
and treated with different proteases as indicated for 1h. Cleavage products were 
detected by western blot using anti C9 antibody. (B) Quantification of the 
Staphylokinase/plasminogen (Skc-Plg)-dependent HA cleavage efficiency. Cleavage 
efficiencies were calculated. The error bars represent the standard deviation of three 
independent experiments, and statistics were performed as in Fig. 4.2. 
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4.2.5 Ch-Pm and Plg mediated HA cleavage is functional and activates the 
virus 
From western blot analysis, it clearly showed that MS96 HA is cleaved by ch-
Pm. Nevertheless, a functional assay was needed to confirm that the cleavage is at 
the correct position and activates the virus. We used a surrogate pseudovirus system 
from mouse leukemia virus (MLV) to produce influenza pseudoviral particles (PV). 
MS96 HA, NA along with MLV-Gag-pol, pTG-Luc are co-transfected into 293T cells 
for 48 hr (Materials and Methods). The harvested PVs were treated differently as 
indicated and the treated PVs were used to infect MDCK cells. Luciferase activities 
were assayed after 2 days post-transduction by lysing the MDCK cells with cell lysis 
buffer. PVs infection is measured by reading of luciferase activities monitoring as an 
indirect method to assay functional HA activation. The data agree with HA cleavage 
results by western blot analysis whereas PV is activated after incubation with ch-Plg 
and sak. HA cleavage is also dependence on P2 tyrosine as MS96 HA-337S PV did 
not show significant activation. We also tested another bacterial co-factor 
streptokinase (ska) and showed very little HA cleavage or activation suggesting a 
bacterial specific HA activation mechanism in MS96 virus (Data not shown).  
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Figure 4.5. Luciferase-based pseudoviral particles (PV) assay of MS96 HA and 
MS96 HA-337S produced in 293T cells. Quantitative HA mediated PV transduction 
assay in MDCK cells. Murine leukemia virus (MLV) based PV with HA and NA on the 
surface were produced in 293T cells described in material and methods. Harvested 
supernatant were underwent different treatments as indicated before infecting MDCK 
cells. Infections were done in duplicates on MDCK cells for 2 days. Cells were lysed 
and relative light units (RLUs) were measured after addition of luciferin. Error bars 
represent 1 S.D. of 3 independent experiments.  
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4.3 Discussion  
The MS96 virus was first isolated in poultry farms in an outbreak in South 
Korea in 1996 (213). MS96 virus was able to spread into four local farms and 
infecting mainly the pullets in these farms. Mortality of chickens infected with MS96 is 
moderately high with a rate of 30%. Clinical symptoms of MS96 infected chickens 
include diarrhea, facial edema and drop in egg production to 0% (248). Necropsy of 
dead chickens revealed swollen kidney with urate deposit and atrophic and ruptured 
ova (249). The MS96 virus was found inside lung, kidney and feces from infected 
chicken, an indication of internal spread of the virus. However standard pathogenicity 
testing of MS96 in 6 weeks old specific-pathogens-free (SPF) chicken in a laboratory 
setting revealed no mortality and MS96 was hence characterized as an LPAI (248). 
The discrepancy between farmed chickens and SPF chickens is unclear. Our data 
suggested that bacterial co-infection may play a significant role in the dramatic 
increase in virulence of MS96 in farmed chickens compared to SPF chickens.  
The MS96 HA is activated by ch-Pm efficiently activated and the process is 
dose dependent and required the S337Y mutation. Differing from WSN, the MS96 HA 
used a totally different mechanism for its HA activation independent of the viral NA. 
MS96 HA hijacks sak, a co-factor from Staphylococcus sp. to activate ch-Plg to ch-
Pm and allow HA activation. This process between MS96 and Staphylococcus sp. is 
species specific as a similar bacterial co-factor skc from Streptococcus sp. shows a 
very weak activity. Such species specificity of MS96 virus and Staphylococcus sp. 
could possibly be explained by the inability of skc in activating ch-Plg. Results from 
the pseudovirus (PV) assay agree with the western blot findings by showing sak-
dependent ch-Plg mediated PV activation. Together, out findings provide evidence for 
Staphylococcus sp. and MS96 synergy in the actual infection in South Korea in 1996.  
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In most cases, influenza viruses overcome the tropism restrictions by mutating 
the HA cleavage site to utilize other unconventional proteases for activation without 
interacting with other pathogens. For instance, highly pathogenic avian influenza 
(HPAI) is able to replicate systemically in animals by acquiring mutations at the 
cleavage site which allow a ubiquitous protease (furin) for activation (151). 
Furthermore, WSN, the neurovirulent mouse-adapted strain of influenza, gains its 
tropism in brain tissue by alteration of HA cleavability by using plasmin (148). In our 
study, we show that MS96 not only interacts with the host, but also with other 
pathogens to setup a unique activation mechanism. Furthermore, we reported AVI 
presumably co-evolves with bacteria and acquires help from bacteria to activate its 
own HA.  
Ideally, challenge experiments in chickens need to be performed to support 
our hypothesis of the influenza-bacteria synergism via interaction between viral HA, 
bacterial sak and ch-Plg. These experiments would also allow us to determine the 
internal spreading of virus inside of infected chicken by determining whether viruses 
can disseminate throughout the body with the help of bacteria. Co-inoculation of 
MS96 and Staphylococcus aureus with an isogenic control of Staphylococcus aureus 
sak in chicken could also be performed.  
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CHAPTER 5 
DISCUSSION, FUTURE DIRECTION AND CONCLUSION 
5.1 Discussion 
 In the 1970s, Dr. Lazarowitz and colleagues discovered that influenza viruses 
require proteolytic cleavage by cellular proteases to initiate successful infection (194). 
The finding was followed by the identification of multiple host and bacterial proteases 
involved in HA activation. However, the localization of many of these proteases does 
not match the natural tropism of influenza viruses. After almost 40 years, in 2006, the 
discoveries of tryptase Clara, TMPRSS2 and HAT have shed light on a group of 
physiologically relevant proteases involved in HA activation (156, 157, 161). Instead 
of searching for other protease candidates involved in HA activation, my studies focus 
on the mechanism of proteolytic activation by these proteases to activate HA in a 
clinically relevant setting. Through a series of experiments, I was able to dissect out 
three distinct mechanisms of HA activation that requires interplay between virus, 
bacteria and host.  
   Since influenza activation is the first step to initiate successful viral infection, it 
is tightly associated with viral pathogenesis and is an important determinant of viral 
tropism and growth kinetics. A single mutation at the HA cleavage site is sufficient to 
alter protease usage or expand the repertoire of protease usage. Using cell surface 
biotinylation, I was able to accurately determine the activation status of HAs on cell 
surface after protease treatments. Such technique allowed me to characterize a Ser 
to Tyr mutation at the P2 position of the HA cleavage site on a human pandemic virus 
that allows Pm to become an alternative protease for activation. After the initial 
characterization, I decided to study the underlying mechanism of Pm usage by this 
HA. Knowing that Plg is the physiologically relevant form of the protease, I focused 
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my study on how Plg gets activated and how it is used by the virus. By employing flow 
cytometry in my study, a technology applied extensively in immunology, I discovered 
that influenza HA can recruit Plg on the cell surface. Since tPA is a membrane bound 
protein, the recruited Plg gets activated into Pm allowing HA activation to occur. To 
my surprise, recruitment of Plg is a general property of influenza HAs suggesting a 
broad usage of such mechanism for other influenza viruses. To my knowledge, this is 
the first reported case of influenza HA actively recruiting a protease to facilitate its 
own activation.  
 Similarly to most of biological processes, other pathways may also be involved 
in Plg-mediated HA cleavage. Instead of searching for other eukaryotic proteins, I 
turned my focus to bacterial proteins and found that skc, a co-factor produced by 
Streptococcus sp. is involved in this process by directly activating Plg.   
 Bacterial co-infection with influenza has always been associated with 
complications of influenza related illness. The synergistic effects between two the 
pathogens are under active research. For instance, lung samples from patients who 
died from the 1918 “Spanish flu“ show signs of extensive bacterial pneumonia 
suggesting that  bacterial co-infection was the main cause of death during that 
pandemic. As bacterial co-infection with influenza virus is a complex, multifaceted 
process, and my findings showed a tight link between bacteria co-infection with 
natural influenza infection.  As a side project, I was able to show that a cysteine 
protease clostripain, produced by the Gram-positive bacteria Clostridium histolyticum, 
is able to activate H1, H2, H3, H7 and H9 HAs. This is the first example of a non-
serine protease cleaving influenza HA (Data not shown).  
 In order to study the HA Ser to Tyr mutation on an actual virus, I used the 
CA0409 reverse genetic system to create two isogenic recombinant viruses with a 
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single polymorphism at the HA cleavage site and tested them in a mouse infection 
model. Although the mouse model did not show any phenotypic difference between 
rCA0409 HA-328Y and rCA0409 WT in both intranasal and intracranial infections, the 
clinical consequence of humans infected by the virus that harbor the mutation Bei718, 
is still undetermined.  
Ser to Tyr mutation is not only limited to human influenza virus, after extensive 
bioinformatic analysis I identified a group of H9N2 AIV harboring an equivalent 
mutation. One virus with well documented clinical data MS96, is of particular interest. 
MS96 shows more severe clinical presentations in chickens found in farm setting than 
specific-pathogen-free (SPF) chickens, suggesting a possible bacterial synergy with 
the virus. By employing similar techniques from the Bei718 research, I discovered 
that MS96 use ch-Pm for HA activation. In contrast to Bei718, MS96 virus completely 
depends on the bacterial mechanism to activate ch-Plg. The hijacking of the S. 
aureus co-factor sak by the MS96 leads to activation of ch-Plg to ch-Pm and 
consequently to HA activation. Interestingly, other bacterial plasminogen activator 
(PA), such as skc from S. pyogenes shows a preference for h-Plg over ch-Plg. Such 
species specificity indicates unique interactions between Staphylococcus sp. and AIV 
as well as Streptococcus sp. and human influenza virus.  
Since the Ser to Tyr mutation at the HA cleavage site clearly showed its 
importance in viral pathogenesis, I decided to determine the crystal structure of an 
uncleaved MS96 HA trimer. In Appendix I, I describe an optimized protocol for 
producing influenza HA trimer using a baculovirus expression system and a 
Drosophila S2 expression system (Data not shown). The optimized system allowed 
production of 2 mg/L of high quality influenza HA trimer after an easy but highly 
specific strep-tactin based affinity purification step which doubled the typical yield of 
 116 
influenza HA production (250). The optimized system was also modified to produce 
influenza NA tetramers (Data not shown) for surface Plasmon resonance (SPR) to 
study the binding kinetics between HA, NA and h-Plg.  
 From the H9N2 AIV study, I uncovered an interesting fact that there are no 
indentified HPAI in the H9 subtype. Despite the fact that all H9 viruses are defined as 
LPAI, number of cases of H9N2 outbreaks showed moderate mortality rate in infected 
chickens, indicating an upward trend in virulence for H9 viruses. This observation 
gave rise to an interesting question: whether H9 influenza is able to convert into 
HPAI. Two groups of researchers took an extreme approach to answer this question 
by creating a chimeric H9N2 virus with a polybasic cleavage site using influenza 
reverse genetics (227, 246). In their chicken infection model, the chimeric virus 
remained LPAI and the authors concluded that the addition of polybasic cleavage site 
does not convert H9N2 to HPAI. However, by heavily depending on the data from a 
single chicken infection model, they overlooked some important details, such as the 
stability of the mutated HA and the mechanism of furin mediated HA cleavage. 
Furthermore, such dramatic change in the cleavage site is not likely to happen in 
nature, a fact that argues against the relevance of their study. With that in mind, I took 
an alternative approach which reflects the natural infection setting to provide some 
answers of this question.  
 By bioinformatic analysis, I found a group of H9 viruses in the Middle East 
harboring a tri-basic cleavage site on the HA. Analysis by athe furin cleavage site 
algorithm Pitou 2.0 predicted that such HA can be cleaved by furin (231). Taking 
Israel810 as a prototypic HA for my study, I showed that HA is not cleaved in 293T 
cells by human furin (h-furin) without addition of exogenous proteases. As HA is a 
protein folded into a complex tertiary structure, the discrepancies between predictions 
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and actual experimental data were well anticipated. To test whether expression levels 
and species specificity play a role in furin mediated cleavage, I decided to clone out 
both h-furin and chicken furin (ch-furin) for further testing. Both ch-furin and h-furin 
are able to cleave Israel810 HA when overexpressed, indicating expression levels of 
the protease is important. However, testing species specific HA cleavage by furin is 
not straightforward since expression levels cannot be easily controlled in transfection.   
I introduced the ProteoTuner Shield System (ppTuner) for transient 
transfection to answer the species specific question. In contrast to the tetracycline 
on/off (Tet-on/off) system which allows analogue control of protein expression, 
ppTuner controls protein expression digitally. The technique is based upon the 
destabilization domain (DD) of FKBP protein which by default is targeted to the 
proteasomes for degradation. By fusing furin to the DD, the fusion protein becomes 
unstable and is constitutively targeted for degradation. A 0.75 kDa membrane 
permeable ligand, shield 1, binds to DD and protects the fusion protein from 
degradation. Therefore, DD-tagged furin levels can be post-translational controlled by 
the amount of shield 1 and are hence, tunable. Using the technique, I was able to 
show that ch-furin is more processive than h-furin in cleaving Israel810 HA and that 
HA cleavage is dose dependent for both furins.  
Although furin levels can be up-regulated by multiple environmental and host 
factors, such processes during an actual influenza infection are still elusive. I decided 
to focus on viral aspects and test if additional mutation would enhance HA activation 
by endogenous furin. A natural occurring mutation, T15R which eliminates a bulky 
sugar moiety found in close proximity to the HA cleavage site, regulates Israel810 HA 
cleavage positively. The two mutations together allow HA activation by endogenous 
furin, a hallmark property of HPAI. After a series of confirmation experiments that 
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include siRNA knockdown and RT-PCR analysis, I was able to show that 
endogenous furin was responsible for Israel810 HA activation in multiple human and 
avian cells.  
Although generation of recombinant viruses with these HA mutations could 
help bolster these findings, the biosafety concerns were not justified for me to 
produce such a potentially highly pathogenic virus. Influenza pseudoviruses (PVs) 
were generated as an alternative approach to study these mutations at the virus level. 
The PV data was coherent with the HA cleavage results indicating that PV was 
activated by endogenous furin. The PV data also suggests that the mutated HA is 
relatively stable compared to HA with a ploybasic cleavage site. Since HA stability is 
an important parameter for viral fitness, my observations might possibly explain why 
polybasic H9 viruses tend to stay lowly pathogenic. The study also suggests that H9 
HA evolved on a different pathway than the one used by H5 and H7, a hypothesis 
that may also explain the absence of HPAI in H9, but multiple moderately pathogenic 
H9 viruses in nature. 
5.2 Future Directions 
 The three mechanisms described above clearly show that the primary and 
tertiary structure of HA tightly controls viral activation and result in modulation of viral 
virulence. For future work, ferret and chicken influenza inflection models should be 
use to determine the possible outcome of Bei718, MS96 and Israel810 virus in 
natural infection setting. Bacterial co-infection model should be preferred to 
consolidate the mechanism of bacteria-influenza synergy in actual infection in vivo. 
HA activation is an attractive target for therapeutic drug development. Indeed, 
the broad-spectrum serine protease inhibitors aprotinin, leupeptin and camostat have 
been used as treatment for influenza infections (251). However, use of aprotinin is 
 119 
associated with an increased risk of renal dysfunction (252). The research on 
protease preferences of individual HAs I have conducted opens up the possibility of 
using a targeted protease inhibitor approach in treating influenza infection. Such 
targeted approach would be beneficial by minimizing potential side effects of 
inhibiting a broad range of serine proteases without massively diminishing the 
antiviral activity of the drug. 
Prevention from influenza infections by vaccination is a critical aspect for 
controlling influenza. Studies on universal influenza antibodies that are able to 
neutralize a broad spectrum of viruses recently generated a lot of exciting results.  
However, some difficulties will be needed to overcome before clinical administration 
can start, including finding an efficient way to elicit universal antibody production in 
vivo and addressing the potential antibody-dependent enhancement (5) problem. 
Moreover, viruses that mutate conserved epitopes targeted by universal antibodies 
will very likely arise after wide administration of such vaccine. Because of some 
limitation of current vaccine production methods, an alternative strategy for vaccine 
production may be needed for the next pandemic. Using knowledge from HA 
activation, we could potentially engineer a fast growing vaccine seed by optimizing 
the HA cleavage site to the corresponding protease for HA activation. For example, 
changing the primary sequence of HA cleavage site to Ala-Asn-Gly-Arg would allow 
efficient viral activation by factor Xa, the protease responsible for HA activation in 
ECE. Furthermore, as our study suggested, Ser to Tyr at the P2 position of HA 
cleavage site may allow faster growth rate of influenza virus in tissue culture.   
Studying sequence and structure of HA cleavage site has no doubt shed light 
on important aspects of the influenza life cycle and the knowledge gained may 
facilitate antiviral drug development that target virus entry into cells. However, 
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transmission of influenza virus is also an important aspect of influenza pathogenesis. 
Knowledge gained from the transmission process can lead to methods alleviating 
influenza transmission in the human population. Similarly to all viruses, influenza virus 
requires environmental cues to initiate different processes during infection. For 
instance, the low pH dependence of HA2 conformational change allows the virus to 
deposit its genome at a precise time inside cells. Although always regarded solely as 
a priming step for influenza viruses, HA activation is possibly time-sensitive and 
needs to be occuring at the correct time and place. Activated HA is less stable than 
its non-activated form due to the exposure of the fusion peptide to exopeptidases 
digestion (253). Therefore, HA activated too early may negatively affect overall viral 
fitness due to protein degradation. In contrast, the limited time from attachment to 
endocytosis (~300 sec) agues in favor of the need for influenza virus to activate just 
prior to reaching the cell surface (254). Therefore, understanding the activation status 
of influenza virus in environment is maybe invaluable in learning more about viral 
transmission. 
Since HA activation controls the infectivity of influenza virus, the activation 
status of the virus in environment prior to entering the host may play a critical role in 
transmission. Therefore, for future work, I hypothesize that the activation status of 
influenza virus affects viral infectivity. And by forcing premature activation and 
conformational changes of HA by modulating the environmental pH for example, we 
can reduce transmissibility of influenza viruses in the environment.   
5.3  Conclusion 
Influenza infection is still a major public health issue globally. In particular, 
during the occasional emergence of a pandemic virus, the field is racing against time 
to better understand the virus. A tremendous amount of time and effort spent by 
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researchers that allowed pushing forward the knowledge on different aspects of 
influenza infections. Thanks to the development of various new sequencing 
technologies, large libraries of influenza sequences can be easily generated. I took 
advantage of the power of bioinformatics combined it with traditional molecular 
biology and biochemistry to elucidate a small yet critical part of the influenza life 
cycle. The knowledge gained from my studies on the primary and tertiary structures of 
influenza cleavage sites and their modulation on viral pathogenesis can potentially 
lead to better treatment options and characterization of influenza virus in general. For 
instance, data from my studies would recommend use of antibiotic as a prophylactic 
treatment for influenza bacterial co-infections to diminish possible synergistic effects 
and disease severity. Another part of my study identified two pathogenic determinants 
of influenza HA and advocates close monitoring for such viruses. Last but not least, 
the mechanisms of protease usage by influenza viruses provide a more thorough 
understanding of this conventional yet critical HA cleavage activation process.   
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CHAPTER 6 
MATERIALS AND METHODS 
6.1 Cells, viruses, plasmids and reagents  
293T/17 (CRL-11268), MDCK.1, MDCK.2 and MDCK (CCL-34) cells 
(American Type Culture Collection, ATCC) were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum 
(Gibco), 100 units/ml of penicillin and 10 g/ml of streptomycin (Cellgro), and 25 mM 
HEPES (Cellgro) at 37oC in a 5% CO2 incubator. DF-1 (CRL-12203), QT-6 (CRL-
1708), Duck Embryo (CCL-141), CGBQ (CCL-169) and LMH (CRL-2117) were 
maintained according to ATCC recommended conditions. The Bei718 HA gene was 
synthesized by GeneArt/Life Technologies based on the sequence in NBCI 
Genebank (accession # ACZ98546), Israel810 HA gene (accession # ABS50802), 
MS96 HA gene (accession# AAF69255) and MS96 NA gene (accession#AZC45243).  
All the hemagglutinin genes were sub-cloned into the pEF4 vector (Invitrogen) 
whereas all H9HAs have an addition of C9-tag at the C-terminus, while 
neuraminidase genes were sub-cloned into the pCAGGS vector unless specified. 
Point mutations were introduced by QuickChange site-directed mutagenesis kit 
(Aglient) following the manufacturer guideline. Human furin and chicken furin were 
cloned from A549 cells and DF-1 cells respectively into pCMV-tag1 (Agilent). TPCK-
trypsin was obtained from Themo Scientific, human plasmin (h-Pm) and plasminogen 
(h-Plg) was obtained from CalBiochem, streptokinase (group C) was obtained from 
Sigma, staphylokinase was obtain form BioVendor Laboratory Medicine, Inc., chicken 
plasminogen (ch-Plg) and chicken-plasmin (ch-Pm) were obtained from Innovative 
Research and 6-aminohexanoic acid was obtained from Alfa Aesar. 
6.2 Influenza reverses genetic  
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 The CA0409 reverse genetic system was a generous gift from Dr. Toru 
Takimoto (University of Rochester). Recombinant influenza viruses, rCA0409 WT and 
rCA0409 HA-328Y were produced as described previously (255). Briefly, 12 plasmids 
were co-transfected in 293T/MDCK cells for 48h using Lipofectamine 2000 
(Invitrogen). The viruses were then plaque purified and amplified on MDCK cells 
grown in DMEM + 0.2% BSA + Hepes (25 mM) + Pen/Strep (10 g/ml) in the 
presence of 3 g/ml of TPCK-trypsin. The HA and NA genes were sequenced and 
confirmed to be free of unwanted mutations. 
6.3 Surface biotinylation and western blot 
293T cells were grown on poly-D-lysine-treated 24 well plates to 60-70% 
confluence and transfected with 500ng of plasmid using Lipofectamine 2000 for 18h. 
Transfected cells were washed with PBS and underwent different treatments in 
DMEM + 0.2% BSA as specified in each experiment. After the treatment, the plates 
were kept at 4oC on ice and were washed with PBS and incubated with Sulfo-NHS-
SS-biotin (250 g/ml, Sigma) for 30 min. Excess biotin was quenched with glycine (50 
mM) for 10 min. Cells were washed with PBS and then lysed by 1x RIPA buffer 
(Millipore) with CompleteTM protease inhibitor cocktail tablets (Roche) for 10 min. 
Lysed cells were centrifuged at 18,000 g for 20 min at 4oC, supernatant was collected 
and added to 30 l of a 50% suspension of streptavidin agarose beads (Thermo) and 
incubated at 4oC on a rotating shaker for 18h to pull down all the biotinylated proteins. 
The beads were washed 3 times with RIPA buffer and resuspended in 30 l of 2x 
Laemmli sample buffer + 10% beta-mercaptoethanol for western blotting. HA bands 
were detected by primary goat -PR8 H0 antibody (BEI Resources, NR-3148) and 
secondary rabbit -goat conjugated to horseradish peroxidase (Thermo) or HA0 and 
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HA2 bands were detected by primary mouse -C9 (ID4) antibody (BEI Resources, 
NR-3148) and secondary goat -mouse conjugated to horseradish peroxidase 
(Thermo). 
6.4 Quantification of HA cleavage 
Western blot images were taken by FujiFilm LAS-3000. The pixel intensity of 
individual band was measured by Image J, and relative cleavage efficiencies were 
calculated by the following equation: [(HA1/HA0+HA1)] x100 or [(HA2/(HA0+HA2)] x100. 
6.5 Immuno-plaque assay 
MDCK cells were grown on 12 well plates to 90-100% confluence. Viruses 
were serially diluted in RPMI and incubated on MDCK cells for 1h at 37oC. MDCK 
cells were washed 2 times with PBS before and after inoculation. Plaque assay 
medium (DMEM + 0.2% BSA + Hepes + Pen/Strep + 1% SeaPlaque Agarose 
(Lonza)) was added along with proteases and/or inhibitors as specified in each 
experiment. Plates were incubated at room temperature for 10 min for the agarose to 
solidify and incubated inversely at 37oC, 5% CO2 incubator for 3 days. Cells were 
fixed in 10% formalin for 1hr and permeabilized with 0.5% Triton X-100 for 3 min. 
Virally-infected cells were detected using primary mouse -nuceloprotein (NP) and 
secondary goat -mouse  conjugated to alkaline phosphatase (JacksonImmuno 
Research). Individual plaque was visualized by adding BCIP/NBT substrate (Vector 
lab). Plaques were counted and viral titers were calculated.   
6.6 Live cell plasminogen binding assay and flow cytometry 
293T cells were grown on 12 well plates to 60-70% confluence and 
transfected with 1 g of plasmid DNA using Lipofectamine 2000 for 18h. Cells were 
washed with PBS gently and incubated in DMEM + 0.2% BSA + Hepes for 30 min at 
37oC to remove any trace plasminogen in FBS. The plates were chilled on ice and 
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cells were detached in 10 mM EDTA for 10 min. Cell pellets were collected by low 
speed centrifugation at 4oC and resuspended in 100 l of 2 M human-plasminogen 
in DMEM + 0.2% BSA + Hepes for 30 min at 4oC on a rotating shaker. Non-bound 
plasminogen was removed by washing 3 times with DPBS. H-Plg was labeled using 
primary mouse -plasminogen (GeneTex) and secondary chicken -mouse Alexa-
647 (Invitrogen). Labeled cells were chilled on ice and immediately analyzed by 
FACS on a LSRII system (BD Biosciences, San Diego, CA). FACS data were further 
analyzed using FlowJo software (Tree Star, Ashland, OR). 
6.7 Viral pathogenesis in mouse model 
For intranasal inoculation, twenty 8-week-old male BALB/c mice, eight for 
each experimental group and four for the PBS control, were inoculated intranasally 
with 105 pfu of virus diluted in 50 µl of PBS. Mouse body weights were measured 
daily for 6 days. Half of the mice were euthanized on day 3 and the other half on day 
6. Indicated tissues were harvested, weighed and stored at -80oC. Immuno-plaque 
assay was performed on 20% tissue homogenate in PBS. For intracranial inoculation, 
thirteen 5 week-old male BALC/c mice were used; four for each experimental group, 
three for the WSN control and two for an artificial cerebral spinal fluid (ACSF, from 
Tocris) control. Each mouse was inoculated intracranially with 103 pfu of virus diluted 
in 5 µl of ACSF, using a Hamilton syringe. Mouse body weight was measured every 
12 h for 3 days. All mice were euthanized on day 3. Brain tissues were collected and 
viral titer determination was performed as described for intransal inoculation. All work 
with animals was carried out according to the Cornell University Animal Care and Use 
program under Animal Welfare Assurance A3347-01, and complied with the Public 
Health Service Policy on Humane Care and Use of Laboratory Animals. 
6.8 Bacterial secondary infection mouse model 
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Sixteen 7-week-old male BALB/c mice, three for each experimental group and 
one for the mock infected control were inoculated intranasally with 105 pfu of virus 
diluted in 50 l of DMEM on Day 0. 106 cfu of bacteria, Streptococcus pyogenes 
NZ131 were diluted in 50 l of THY medium and inoculated intranasally on Day 3 
post-infection. Mouse body weights were measured daily for 7 days. All the mice were 
euthanized on Day 7.  
6.9 Tunable expression of chicken (ch) furin and human (h) furin 
Ch-furin and h-furin were cloned into pPtunerC from Clontech using EcoRI 
and SalI restriction site. pPtunerC-ch-furin-DD or pPtunerC-h-furin-DD (200 ng) were 
co-transfeced with pEF4-Israel810HA (300 ng) into 293T cells. Shield 1 (Clontech) 
was added at 6h post-transfection and surface biotinylation and western blot were 
done as described above. 
6.10 siRNA knockdown assay 
293T cells were grown on poly-D-lysine-treated 24 well plates to 60-70% 
confluence and co-transfected with pEF4-HA plasmids and either ON-TARGETplus 
Non-Targeting siRNA or ON-TARGETplus Furin siRNA (Thermo) using DharmaFECT 
Duo (Thermo) for 24 hr following the user manual. Half of the cells were used to 
perform surface biotinylation to determine HA cleavage. The other half of the cells 
was harvested for Q-RTPCR to determine knockdown efficiency.  
6.11 Quantitative reverse transcribed polymerase chain reaction (Q-RTPCR) 
 Approximately 1x106 -1x107 cells were harvested and spun down at 300g for 5 
min at 4oC. Total RNA from the cell pellet was purified by RNeasy mini kit (Qiagen) 
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following the manufacturer guideline. RNA concentration was measured by a UV 
Spectrophotometer Q3000 (Quawell) and the quality was confirmed by 260/280 ratio, 
with the values ranging between 2.1-2.2. One-step Q-RTPCR was performed using 
QuantiTect SYBR Green RT-PCR Kit (Qiagen) following the user manual with 50 ng 
of RNA input. Human furin primers were acquired from PrimerBank 
(http://pga.mgh.harvard.edu/primerbank/) (256-258). Primer pairs for h-furin 
(PrimerBank ID: 20336193c1), primers for h-GAPDH, chicken-furin and ch-GAPDH 
were ordered from QuantiTect Primer Assays (Qiagen). Reactions were setup on ice 
on a 96-well plate and were run immediately using an Applied Biosystems (AP) 7500 
Fast Real-time PCR system. The amplification plot and dissociation curves were 
analyzed by the 7500 Fast Real-time PCR software to determine the threshold cycles 
and dissociation of the each sample. Furin expression level was compared relatively 
to GAPDH expression and normalized to either 293T cells alone (Fig. 6C) or no 
siRNA treatment (Fig. 4C). 2-DDCt was calculated as described previously (259).  
6.12 MLV-based influenza pseudoviral particles (PV) transduction assay 
 To produce MLV based PV, 293T cells were grown on 12 well plates to 50 – 
60 % confluence and transfected with MLV-gag-pol (350 ng), pTG-luc (500 ng), 
A/chicken/Korea/MS96/1996 (H9N2), Accession # AAF10404) neuramindase (NA) 
(350 ng), HAs (350 ng) and furin plasmids (350 ng, specified in individual experiment) 
for 48h using Lipofectamine 2000. Supernatants were harvested and filtered through 
0.45 µm filter to remove any cell debris. The filtered supernatants containing PV were 
treated with or without trypsin (3 g/ml) as specified in each experiment for 15 min at 
37oC to allow HA activation. After activation, excess trypsin activity was neutralized 
by addition of a 1:1 ratio of RPMI containing trypsin inhibitor from Glycine max 
(soybean) (Sigma-Aldrich). MDCK cells were grown on 24 well plates to 60 – 70 % 
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confluence and infected in duplicate by 200 l of PV-RPMI mixture for 1h. 500 µl of 
DMEM + 2%FBS + Hepes + P/S was added to each well and incubated for 48h for 
transduction. Cells were lysed by 1x cell culture lysis reagent (Promega) for 1h at 
room temperature on a rocker. Transduction efficiency is measured as RLUs using a 
GloMax-20/20 luminometer (Promega) by mixing 10 l of lysate and 20 l of 
luciferase assay reagent (Promega).    
6.13 Ch-Plg activation by Staphylokinase (sak) 
 Staphylokinase (100 g/ml) and ch-Plg (50 g/ml) were pre-incubated in 20 
mM Tris pH 7.5 for 1.5h at 37oC before treatment and use as a 10x solution 
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APPENDIX 1 
PRODUCTION OF INFLUENZA HA BY THE BACULOVIRUS EXPRESSION 
SYSTEM 
A1.1 Introduction 
 As fundamental building blocks of living organism, proteins play an important 
role in any biological processes. In order to study protein in great detail, a large 
amount of purified protein is often required. However, the quantity of proteins varies 
and could be very low in physiological conditions, which impose a big challenge to 
study. The invention of cloning and recombinant expression of protein in the 80s 
allows the field to move forward (260). The concept behind recombinant proteins is 
simple; protein of interest is cloned and mass-produced in a surrogate system, which 
allow efficient production of any proteins. Bacterial and yeast expression system are 
the two common systems for protein expression due to the rapid grow rate of the two 
organisms. Although the two systems cover protein production for prokaryotes and 
eukaryotes, some proteins are not optimal for the systems intrinsically. 
 Viral envelope proteins are of great interest not only because of their 
importance for viral life cycle, but also because they are the major antigenic 
determined for their host. Most of the viral envelope proteins are folded in complex 
structure and are highly glycosylated, which is not ideal for the generic expression 
system. Alternative expression systems were used to product recombinant viral 
envelope protein; including insect and mammalian cell expression systems. After a 
series of intensive optimization, both of them are able to produce a reliable amount of 
proteins. In here, we were able to modify the existing baculovirus system in our 
laboratory to produce large quantity and high quality of influenza hemagglutinin trimer 
(HA) for crystallography. The modified system allows efficient secretion of the HA and 
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a small affinity tag for one step purification. This system is already optimized and will 
require minimum effort to apply to other viral envelope proteins. 
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Figure A1.1. Construct designs of influenza HA trimer and NA tetramer 
production by the baculovirus expression system. (A) Construct of recombinant 
MS96 HA trimer for crystallography.  The ecto-domain of influenza HA is fused with 
the melittin secretion peptide from honeybee at the N-terminus for efficient secretion 
(261).  T4 fibrintin foldon from T4 bacterial phage is fused to the c-terminus of the HA 
to facilitate HA trimerization.  The constructs use a nine amino acid long strep-tagII at 
the c-terminus for affinity purification. A prescission cleavage site is introduced 
between the HA and T4 foldon for removal of all the heterogeneous sequence from 
the HA after purification. From our design, the final product is just the ectodomain of 
HA trimer. (B) Construct of recombinant influenza HA trimer and (C) NA tetramer for 
surface plasmon resonance experiment (SPR). Tetramerization domain synthesized 
based on human vasodilator – stimulated phosphoprotein. 
 
A 
 
B 
 
C 
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 Figure A1.2. Schematic of MS96ce6 trimer production by the baculovirus 
expression system. 
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Figure A1.3.  Conditions of MS96ce6HA trimer production. 
 
Cell  Sf9 adopted in Sf900 III SFM (5x106 cell/ml, 95% viability)  
Virus  Baculovirus-156 P3 (3x107pfu/ml)  
MOI  ~0.5  
Medium  Sf900III SFM  
Volume  500 ml (400 ml cells + 50 ml virus + 50 ml fresh medium)  
Flask  2000 ml Erlenmeyer flask  
Duration  4 days  
Temperature  27 – 29oC  
Rpm  120  
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Figure A1.4. Purification of recombination MS96ce6 HA by affinity 
chromatography. (A) Conditions of affinity chromatography using strep-tactin bead. 
(B) SDS-PAGE of purified MS96ce6 HA from supernatant, Elute 1 – 10.  
A 
ASupernatant  Spin  @ 4000 rpm for 40 min, @ 4oC Add to 10% glycerol  
Affinity Bead  10 ml Strep-tactin Incubate O/N on rocker and roller  
Elution Buffer  100 nM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 10% glycerol pH 
8.0  
Elution Volume  10 times, 5 ml each  
 
B
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Figure A1.5. Purified MS96ce6HA ecto domain after HRV3c cleavage. (A) 
Conditions of HRV3c treatment. (B) SDS-PAGE of recombinant MS96 HA after 
HRV3c treatment. 
A 
Rxn Buffer  500 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, pH 7.55  
Enzyme  0.2 mg HRV3c from A.G. Scientific  
Temperature  4oC  
Duration  16 h  
 
B 
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APPENDIX 2 
IMMUNOPLAQUE ASSAY (INFLUENZA VIRUS) 
Abstract 
 Despite developed a long time ago, plaque assay is still the gold standard for 
viral titer quantification in modern virology. The standard crystal violet-based plaque 
assay relies on virus’ ability to induce cytopathic effect (CPE) which limits the assay 
to lytic viruses. Alternative viral quantification assays such as 50% tissue culture 
infectious assay (TCID50) and genetic material quantification by Q-PCR provide a 
different way of viral quantification with their own shortcoming. In here, we modified 
the fluorescent focus assay and developed an antibody-based immunoplaque assay 
which provides a reliable and reproducible viral quantification independent of CPE. 
Our assay not only allows accurate determination of viral titer, but also provides 
information on viral kinetics, genetic stability and purity of the virus population. 
A2.1 Materials and Reagents   
1. MDCK cells. Please note that there are multiple variants of MDCK on 
American Type Culture Collection (ATCC). This protocol has been tested for 
MDCK (CCL-34), MDCK.1 (CRL-2935) and MDCK.2 (CRL-2936) 
2. Recombinant A/California/04/2009 virus produced from 12 plasmids reverse 
genetic system (Generous gift from Professor Toru Takimoto from University 
of Rochester, New York, USA) (255) 
3. Trypsin/EDTA (Cellgro, catalog number: 25-053-CI) 
4. 2% SeaPlaque Agarose in ddH2O (Lonza, catalog number: 50100) 
5. TPCK-Trypsin (Thermo, catalog number: 20233) 
6. PBS without Ca2+ and Mg2+ (Cellgro, catalog number: 21-030-CV) 
7. DPBS with Ca2+ and Mg2+ (Cellgro, catalog number: 21-040-CV) 
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8. 10% formalin (Sigma-Aldrich, catalog number: HT501128-4L) 
9. TritonX-100 (Sigma-Aldrich, catalog number: T9284) 
10. 5% goat serum in DPBS (Gibco, catalog number: 16210-072) 
11. Mouse anti-NP antibody from hybridoma: H16-L10-4R5 (ATCC, catalog 
number: HB-65) 
12. Alkaline phosphatase conjugated Donkey anti-mouse antibody (Jackson 
Immuno Research, catalog number: 715-056-150) 
13. Alexa Fluor 488 conjugated Goat anti-mouse antibody (Invitrogen, catalog 
number: A11001)  
14. BCIP/NBT substrate (Vector Laboratories, catalog number: SK-5400) 
15. DMEM (Cellgro, catalog number: 10-017-CV)  
16. DMEM powder (Cellgro, catalog number: 50-003-PB) 
17. Heat-inactivated fetal bovine serum (Gibco, catalog number: 26140079) 
18. HEPES (Cellgro, catalog number: 25-060-CI) 
19. Penicillin/Streptomycin (Cellgro 30-002-CI) 
20. 7.5% BSA Fraction V (Gibco, catalog number: 15260) 
21. RPMI 1640 powder (Cellgro, catalog number: 50-020-PB) 
22. Tris base (US Biological, catalog number: T8600) 
23. Sodium chloride (NaCl) 
24. Magnesium chloride (MgCl2) 
25. Sodium hydroxide (NaOH) 
26. Complete DMEM (cDMEM) (see Recipes) 
27. 2x DMEM (see Recipes) 
28. RPMI (see Recipes) 
29. Alkaline phosphatase (AP) reaction buffer (see Recipes) 
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A2.2 Equipment 
1. Standard tissue culture equipment  
2. 12-well tissue culture plate 
3. 37 °C 5% CO2 cell culture incubator 
4. Inverted fluorescence microscope (Optional) 
5. Rocker 
6. Laboratory spatula 
7. Heated stir plate 
8. Vortex 
9. Axiovert 200 microscope 
A2.3 Software 
1. IPlab3.6.5 software 
A2.4 Procedure 
Day1 
1. Each well on a 12-well-plate is seeded with 5 x 105 MDCK cells suspended in 
1 ml of cDMEM. 
2. The plate is incubated in the 5% CO2 incubator at 37 °C overnight. 
Day2 (or until cells reach 95% - 100% confluence) 
3. Viruses are serially diluted (10-fold) in RPMI, vortex each dilutions and keep 
on ice before use.  
4. MDCK cells are rinsed with 1 ml of DPBS twice. 
5. MDCK cells are inoculated with 500 μl of viruses prepared from step 3. 
6. The plate is incubated in 5% CO2 incubator at 37 °C for 45 min. 
7. Prepare SeaPlaque DMEM (pDMEM) 
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a. 2x DMEM is warmed at 37 °C water bath and 2% SeqPlaque agarose is 
melted on a hot plate at about 45 – 50 °C with stirring (*The cap should be 
slightly released to prevent pressure buildup). 
b. To obtain pDMEM, pre-warm 2x DMEM and 2% agarose are mixed in 1:1 
ratio in a sterile container and sit at room temperature for 5–10 min to cool 
down. 
c. TPCK-trypsin (final concentration: 1 μg/ml) is added to the pDMEM. 
8. Viral inoculums are aspirated and MDCK cells are rinsed with 1 ml of DPBS 
once.  
9. 1.5 ml pDMEM + TPCK-trypsin from step 7-c is added to each well. 
10. The plate is sat at room temperature (RT) for 10–15 min until pDMEM solidify. 
11. The plate is incubated at 5% CO2 at 37 °C in the invert orientation (lid at the 
bottom) for 3 days. 
Day 5 (or until visualization of plaque) 
12. MDCK cells are fixed by adding 1.5 ml of 10% formalin directly on top of the 
agarose and incubated at RT for 2 h. 
13. Extra formalin is aspirated and agarose from the well is removed and trashed 
carefully without disturbing the monolayer of cell using a laboratory spatula or 
equivalent tools. 
Note: Experiment can be stopped after this step by adding PBS to cover the cells and 
store at 4 °C. 
14. MDCK cells are permeabilized by 300 μl of 0.5% Triton-X100 in DPBS for 5 
min on bench without agitation. 
15. Cells are rinsed with 1 ml of PBS twice. 
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16. Cells are blocked by 300 μl of 5% goat serum in DPBS for 30 min at RT with 
agitation on rocker. 
17. Cells are incubated with H16-L10-4R5 antibody (1:40) in 300 μl of 5% goat 
serum for 1 h at RT with agitation on a rocker. 
18. Cells are rinsed with 1 ml of PBS twice. 
19. Cells are incubated with alkaline phosphatase conjugated donkey anti-mouse 
(1:1,000) in 300 μl of 5% goat serum for 45 min at RT with agitation on a 
rocker. 
20. Cells are rinsed with 1 ml of PBS twice and AP reaction buffer once. 
21. Prepare the BCIP/NBT solution 
a. Added 2 drops of solution A, B and C into every 5 ml of AP reaction buffer. 
b. Mix by inverting the tube for 4–6 times. 
22. 300 μl of BCIP/NBT solution is added to each well. The plate is put on a 
rocker in dark for 30 min or until the development of color.  
23. The reaction is stopped by rinsing the plate with ddH2O.  
24. The plate is air-dried at RT. 
25. Count the number of plaques, check the plaque morphology and measure the 
size of plaques. 
Alternative visualization method by fluorescence, fluorescent focus assay (FFA)  
(Continuous from step 18) 
19.1 Cells are incubated with goat anti-mouse Alexa Fluor 488 antibody (1:1,000) 
in 300 μl of 5% goat serum for 45 min at RT in dark. 
20.1 Cells are rinsed with 1 ml of PBS twice. 
21.1 Cells are covered with 500 μl of DPBS and store at 4 °C. 
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22.1 Check the plaque morphology and measure the size of plaques using an 
inverted  fluorescence microscope. 
Note: The protocol is optimized for influenza viruses. Modifications may be 
required for use in other viruses. For instance, factors required for multiple rounds 
of replication of the virus should be added in the pDMEM.  
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Figure A2.1. Diameter of Individual Plaque of A/California/04/2009/H1N1 
Recombinatant Viruses (rCA0409). (A) Quantification of the diameter (μm) of 100 
individual plaques of two different CA0409 viruses, wild type (WT) and HA-S328Y 
mutants (HA328Y). Images are taken by Axiovert 200 microscope using a 5x 
objective and diameters of each plaque are measured by IPlab3.6.5 software. 
Statistics are done by one-tail Student’s t-test. (B) Representative image of plaques 
of CA0409 viruses stained with Alexa Fluor 488, scale bar = 200 μm. Images are 
taken by Sensicam using IPlab 3.6.5. 
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